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Summary
This thesis describes eﬀorts in synthesising and investigating new tumour-seeking agents for
targeted radiotherapy of malignant melanomas and bone-related cancers. The concept of
targeted radiotherapy is presented, and selection criteria for therapeutic radionuclides are
discussed. Emphasis has been given to the heavier radiohalogens (radioiodine isotopes and
211At) and their labelling chemistry.
Three classes of melanoma-seeking agents have been treated; phenothiazines, cyste-
aminylphenols and benzamides. Stannylated derivatives of the two latter groups were success-
fully synthesised and radiohalogenated, resulting in six potential melanoma-seeking agents
labelled with radioiodine or 211At. Melanoma aﬃnity and in vivo stability were investi-
gated in mice bearing the human melanoma xenografts HHMSX (pigmented) or SESX (non-
pigmented). Four derivatives showed high stability to enzymatic dehalogenation in vivo,
but only the radioiodinated benzamide [125I]IMBA demonstrated promising tumour accu-
mulation and retention in the melanoma models. The results supports previous suggestions
of using [∗I]IMBA in scintigraphic imaging of pigmented and non-pigmented melanomas.
[∗I]IMBA may also have a future in scintigraphic imaging of other cancers expressing a high
density of sigma-receptors.
The bone-seeking iodobisphosphonate [∗I]HIPEBA was labelled with 123I, and its po-
tential for clinical applications in humans was investigated in young pigs. Initial phar-
macokinetic properties were studied using dynamic and static gamma-camera imaging,
showing superior bone uptake and negligible renal excretion of [123I]HIPEBA compared to
99mTc-MDP. Estimated radiation doses in humans indicated similar radiotherapeutic prop-
erties for [131I]HIPEBA and 153Sm-EDTMP. Hence, [∗I]HIPEBA is a promising candidate for
diagnostic imaging and targeted radiotherapy of osseous lesions, and further evaluations in
humans are justiﬁed.
The thesis gives an extended overview of the work, presenting additional experiments and
results to those described in the papers.
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Chapter 1
Introduction
The prognosis of surviving cancer has improved over the years. However, only 50% of Nor-
wegian patients are alive ﬁve years post-diagnosis [1]. Hence, development of more eﬃcient
cancer treatments is a major challenge in cancer research.
Successful curative therapy requires complete removal or destruction of malignant cells.
However, for many malignancies there are no eﬀective treatment for patients with exten-
sive metastatic spread of the disease. Advances and research in alternative and improved
treatment methods for metastatic cancer disease are highly required.
Systemic targeted radiotherapy is a promising modality for treatment of disseminated can-
cers. The concept is based on selective irradiation of malignant cells by means of radionuclides
attached to ”tumour-seeking” molecules. Interest in this treatment modality has increased
over the years due to new developments of available radionuclides and carrier molecules.
In this thesis focus has been on developing new radiopharmaceuticals for targeted radio-
therapy of two diﬀerent forms of cancer where standard treatment modalities have failed
or have had limited success. Part I presents therapeutic radionuclides for targeted radio-
therapy, with emphasis on radioiodine isotopes, the α-emitter astatine-211 and their labelling
chemistry. Part II presents the eﬀorts in developing new radiohalogenated melanoma-seeking
agents for diagnosis and targeted radiotherapy of metastatic malignant melanomas. Part III
concentrates on the investigation of a radioiodinated bisphosphonate with potential in pallia-
tive treatment and targeted radiotherapy of osteosarcoma and bone metastases.
3
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Background
2.1 Targeted radiotherapy of cancer
When tumours or metastases cannot be removed by surgery, the conventional therapeutic
approach is external beam radiotherapy and chemotherapy. However, these treatments show
low selectivity for cancer cells and tumour tissues, and might be damaging or cytotoxic to
healthy tissues when applied at curative levels.
An attractive alternative is to exploit a biological or chemical characteristic of the speciﬁc
cancer or the aﬀected tissue. In favourable cases, molecules with aﬃnity for a specialised
biological feature may function as speciﬁc, ”tumour-seeking” agents (e.g. antibodies, anti-
body fragments, peptides, small molecules with tumour aﬃnity). Targeted radiotherapy in-
volves such agents incorporating a suitable therapeutic radionuclide, ideally giving site-speciﬁc
radiation treatment of the primary tumour and its metastases while producing minimal ra-
diation damage to surrounding normal tissues [2]. Thus, the choice of carrier molecule and
radionuclide must be adjusted to the type of tumour or metastasis with regard to biological
properties, size, geometry and localisation relative to dose-limiting organs.
2.2 Therapeutic radionuclides and radiobiology
Important criteria in the choice of suitable therapeutic radionuclides include physical, chemi-
cal, biological and economical aspects. Methods for rapid and speciﬁc labelling chemistry
producing radioactive agents with a chemically stable label are crucial. The half-life of the
radionuclide must allow time for chemistry, puriﬁcation, logistics and maximal (intra)cellular
retention when distributed in vivo. The energy deposition of the emitted radiation must
be considered, and the daughter nuclide(s) should have properties minimising the radiation
burden to healthy tissues. The selection of therapeutic radionuclides is furthermore limited
5
6 Background
by cost and availability [3].
After considering these restrictions, a suitable therapeutic radionuclide is essentially cho-
sen due to the quality of the emitted radiation expressed by the linear energy transfer (LET).
In terms of causing a biological eﬀect (irreparable damages to DNA, cell death), the focus
is set on ionising radiation from radionuclides emitting charged particles [4]. Particles with
high ionisation densities (high LET-values) have a direct interaction with tissue, inducing irre-
pairable double strand breaks in DNA. This eﬀect is optimal for particles having a LET-value
about 100 keV/μm, i.e. when the distance between ionising events along the particle track
coincides with the distance between the strings of the DNA double helix [5]. Particles with
low LET-values predominantly have an indirect interaction with tissue caused by radiation-
induced radicals. Thus, the probability of inducing irreparable double strand breaks in DNA
is strongly reduced. However, the eﬀect of low-LET radiation depends not only on the applied
radiation dose, but also on dose rate, number of dose fractions, the cell cycle and the use of
radioprotectors and radiosensitisers [5].
Clinical radionuclide therapy has so far been limited to a few β−-emitting radionuclides
and a few types of tumours [2, 6].
2.2.1 Radionuclides emitting β-particles
The majority of current clinical applications in targeted radiotherapy involve the β−-emitters
131I, 32P, 90Y and 89Sr [7, 8]. The β-particles have low LET-values (range 0.2–1.0 keV/μm)
and a modest relative biological eﬀectiveness (RBE). However, β-emitters are readily available
at low cost and oﬀer a wide choice of candidates in terms of particle energies and chemical
properties. The emitted β-particles have a tissue range of several millimeters (Table 2.1)
and are well suited for treatment of larger tumour masses and tumours with a heterogenous
uptake (through crossﬁre irradiation). The use of highly energetic β-particles is restricted by
the radiation burden and cell damages to surrounding healthy tissues, and especially by the
suppression of activity in red bone marrow.
2.2.2 Radionuclides emitting α-particles
The use of α-emitting radionuclides has a major advantage in radiotherapy of cancer. The
α-particles have mean LET-values of 80–100 keV/μm, close to maximal RBE and a cell-killing
eﬃciency independent of biological and chemical factors [5]. The high cytotoxicity and short
tissue range (30–100 μm) restrict the cell-killing to a few cells surrounding the α-emitting
radionuclide [9]. Thus, a carrier molecule incorporating a suitable α-emitter might induce a
radiotherapeutic eﬀect on tiny clusters of cancer cells, micrometastases and single-cell diseases,
minimising the radiation doses to red bone marrow and healthy tissues.
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Table 2.1: Data on some potential radionuclides for targeted radiotherapy.
Nuclide Half- Decay Eβ max Eα max γ-energy Mean particle
life modea (MeV) (MeV) (keV)b tissue range
32P 14.26 d β− 1.7 - - ∼ 3.0 mm
89Sr 50.5 d β− 1.5 - (909) ∼ 2.4 mm
90Y 64.1 h β− 2.3 - (2186) ∼ 3.6 mm
117mSn 13.6 d e− - - 159 0.3 mmc
125I 59.41 d ECd, e− - - 35 ∼ 1 μm
131I 8.02 d β− 0.6 - 364 ∼ 0.7 mm
149Tb 4.1 h EC, α, β+ 1.8 3.97 352 ∼ 28 μme
153Sm 46.27 h β− 0.7 - 103 ∼ 0.8 mm
166Ho 26.8 h β−, e− 1.9 - 81 ∼ 3.2 mm
177Lu 6.71 d β− 0.5 - 208 ∼ 0.5 mm
186Re 89.25 h β−, EC 1.1 - 137 ∼ 1.1 mm
188Re 16.98 h β− 2.1 - 155 ∼ 3.4 mm
211At 7.22 h EC, α - 5.87 (687) 55–80 μm
212Bi 60.6 min β−, α 2.3 6.05 727 50–90 μme
213Bi 45.59 min β−, α 1.4 5.87 440 50–90 μme
223Ra 11.43 d α - 5.72 269 < 100 μm
224Ra 3.66 d α - 5.69 241 < 100 μm
225Ac 10.0 d α, e− - 5.83 100 < 100 μme
227Th 18.7 d α, e− - 6.04 236 < 100 μme
255Fm 20.1 h α, sf, e− - 7.02 (81) ∼ 100 μme
a EC = electron capture, e− = conversion electrons, β− = electron emission,
β+ = positron emission, α = alpha emission, sf = spontaneous ﬁssion.
b Intensities <1% are given in brackets.
c Conversion electrons emitted by 117mSn are monoenergetic (0.13 MeV).
d Abundance of Auger-electrons >100%.
e The α-particle range.
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Only a few α-emitters are suitable for targeted radiotherapy of cancer, e.g. 211At, 212Bi,
213Bi, 223Ra, 224Ra, 225Ac, 227Th, 255Fm and 149Tb (Table 2.1) [9, 10]. Among these, only
211At, 212Bi, 213Bi and 223Ra have been extensively evaluated in vivo for use in cancer therapy.
The bismuth-isotopes are bound to chelating agents by complexation [11, 12], while 223Ra
simply is used as 223RaCl2 [13]. Astatine is chemically quite similar to iodine and can be
incorporated into an aromatic compound by covalent bonding [14–16]. The isotope 211At has
been regarded as the most promising and versatile α-emitter studied for radiotherapy of cancer
so far [3, 15].
2.2.3 Radionuclides emitting low-energy electrons
Other therapeutical alternatives are radionuclides emitting Auger- or low-energy conversion
electrons (Table 2.1). These particles are characterised by a high ionisation density over
a very short range in tissue; ∼0.3mm for conversion electrons and subcellular (∼1μm) for
Auger-electrons [2, 17–19]. Thus, a maximal radiobiological eﬀect is obtained when the
Auger-electron emitters are located within the nuclei of cancer cells.
A future possibility in targeted radiotherapy is to combine the eﬃcient single-cell killing
properties of α-particles and DNA-associated Auger-emitters, with β-particles eliminating
larger malignancies mainly by crossﬁre irradiation.
2.2.4 Radionuclide pairs for imaging and radiotherapy
The dosimetry of radionuclide therapy depends on quantitative in vivo uptake measurements
of the therapeutic agents. Pre-therapy imaging, particularly positron emission tomography
(PET), can improve the accuracy of such estimates provided that two radionuclides of the
same element are used successively for imaging and radiotherapy. Examples of such radio-
nuclide pairs for PET-imaging/radiotherapy are 83Sr/89Sr, 86Y/90Y and 124I/131I. The radio-
nuclide 64Cu is also very interesting as it combines β+-, β−- and Auger-electron emissions in
its decay [7].
2.3 Radiohalogens
Several radiohalogens are important in the development of new radiopharmaceuticals aiming
at diagnostic imaging or radiotherapy [16]. Radiohalogens emitting high yields of photons
with an energy of 100–400 keV (e.g. 123I) may be used in single photon emission computed
tomography (SPECT). The positron-emitting radiohalogens 18F, 75Br, 76Br and 124I are
interesting for PET-imaging [20], while radiohalogens emitting α-particles, β−-particles or
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Auger-electrons have properties suitable for radiotherapeutic applications. In this thesis, the
radionuclides 123I, 124I, 125I, 131I and 211At deserve special attention.
2.3.1 Important radioiodine isotopes
The 123I (t1/2 13.2 h) decays through electron capture with emission of 159 keV γ-rays, result-
ing in almost optimal gamma-camera performance in SPECT. This radionuclide also emits
Auger-electrons, thus it may be an attractive candidate for radiotherapeutic applications.
The 124I (t1/2 4.15 d) disintegrates by electron capture and emission of up to 2.13MeV β+-
particles. The radionuclide beneﬁts from a longer half-life than most standard PET-isotopes,
but high-energy positrons might result in loss of spatial resolution in PET-images compared to
18F. Emission of high-energy γ (>603 keV) may be a limiting factor for clinical applications.
The 125I (t1/2 59.41 d) disintegrates by electron capture, emitting 35 keV γ and conversion
electrons. The emission of Auger-electrons makes 125I an interesting radionuclide for micro-
tumour therapy, but the physical half-life is too long for clinical applications. Hence, this
radionuclide is mainly used preclinically due to its easy handling and storage.
The 131I (t1/2 8.02 d) disintegrates by β−-decay (0.6MeV) with a main accompanying
γ-energy of 364 keV. The radionuclide is considered suitable for therapeutic applications, but
it is not ideal for imaging purposes due to the radiation dose caused by the emitted β−-
particles. However, 131I is the most commonly used radionuclide in radiotherapy, particularly
in the treatment of thyroid cancers and non-malignant thyroid disorders.
2.3.2 Astatine-211
The α-emitting radionuclide 211At (t1/2 7.22 h) disintegrates following a branched decay
scheme as illustrated in Figure 2.1. In the ﬁrst branch, the 211At decays by emission of
5.87MeV α-particles to 207Bi (t1/2 31.55 y), which disintegrates by electron capture to stable
211Po207Bi
211At
207Pb
0.52 s
7.22 h
31.55 y
stable
58% EC
100% alphaEC (beta+)
42% alpha
Ealpha = 7.45 MeV
Ealpha = 5.87 MeV
Figure 2.1: Decay scheme for 211At.
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207Pb. The second branch involves decay by electron capture to 211Po (t1/2 0.52 s), followed
by an emission of 7.45MeV α-particles giving stable 207Pb. Hence, the mean energy of the
emitted α-particles is 6.7MeV, resulting in a mean LET value of 97 keV/μm and a tissue
range corresponding to 55–80 μm from the point of decay. This high LET-value and short
tissue range make 211At particularly attractive for radiotherapy of micrometastatic cancers or
in applications where single cells are targeted. However, diﬀusion of the 211Po daughter might
reduce the total tumour radiation dose [21]. Decay of 211Po results in polonium K X-rays
(77–92 keV) which enable sample-detection as well as external imaging using SPECT. The
general use of astatine is limited by the lack of long-lived astatine-isotopes and few production
facilities for 211At.
2.4 Radiohalogen labelling chemistry
Several requirements have to be fulﬁlled when labelling a compound with a radionuclide. In
general, the labelling chemistry should be fast, regiospeciﬁc, reproducible and give a stable,
labelled product in high radiochemical yield. With short-lived radionuclides, labelling in the
last reaction step is often advantageous, reducing the loss of radioactivity, time for synthesis
and puriﬁcation as well as exposure. The speciﬁc radioactivity of the product should normally
be as high as possible (starting with no-carrier-added radionuclides), and the compound
should retain its original biological properties after radiolabelling. Radiolysis has to be taken
into account in the labelling procedure, particularly when using high-LET radionuclides like
211At [22, 23]. The in vivo stability of the radiolabelled product is of paramount importance
if the substance is to be used as a radiopharmaceutical. Thus, the choice of labelling method
is crucial for an optimal production of a radioactive preparation.
Most radiohalogenations (except for ﬂuorinations) are conducted as electrophilic substitu-
tion reactions. Electrophilic reactions require formation of an electrophilic radiohalogenation
reagent through oxidation of halide ions:
X−  Xδ+
Electrophilic halogen species can be obtained in situ by using various oxidising agents,
e.g. chloramine-T, tert -butyl-hydroperoxide (TBHP), N -chlorosuccinimide (NCS) and
N -iodosuccinimide (NIS) [24].
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2.4.1 Direct radiolabelling of small aromatic compounds
Strongly activated aryl compounds (e.g. phenols, anilines and N -alkyl-anilines) are readily
radiohalogenated via a direct electrophilic halogenation using an appropriate oxidising agent:
Ar–H + ∗Xδ+–Xδ− → Ar–∗X + H–X where X = Cl, Br, I or
Ar–H + ∗X+–A− → Ar–∗X + H–A
where ∗X is the radiohalogen and A is a more electronegative group than ∗X. The
radiolabelling reaction will primarily give monohalogenated products with the radiohalogen
incorporated ortho or para to the activating substituent. Direct halogenation may also
be used for moderately activated aryl compounds, but the radiochemical yields might be
signiﬁcantly reduced due to side reactions.
Direct electrophilic radioiodinations are very common, giving aryliodides with high chemi-
cal stability [24, 25]. Direct electrophilic ﬂuorinations, chlorinations and brominations require
harsh oxidising conditions, while astatinations give products with poor stability due to weak
carbon–astatine bonds [26]. For example, the phenolic ring is too activated to produce sta-
ble compounds with astatine [25]. A limitation of this labelling method is the formation of
isomeric product mixtures which may be diﬃcult to separate.
2.4.2 Indirect radiolabelling of small aromatic compounds
Radiohalogens can be labelled regiospeciﬁcally into moderately or non-activated aromatic
rings using indirect labelling methods. The two most common methods include incorporation
of radiohalogens via decomposition of aryl diazonium salts or via organometallic intermedi-
ates [24, 25]. For labelling reactions with radioiodine and 211At, the use of organometallic
precursors or compounds incorporating an organoboron cage are preferred [27].
Halodemetallations are used for regiospeciﬁc labelling of a substrate molecule at the
organometallic site, giving radiohalogenated products in high radiochemical yields using mild
labelling conditions and short reaction times. Diﬀerent organometallic intermediates have
been studied, e.g. organothallium compounds, organomercury compounds, organostannanes,
organosilanes and organogermanes. The outcome of a halodemetallation is aﬀected by the
metal, chemical labelling conditions as well as steric factors [14, 24].
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Halodemetallation with group 14 metals
Organometallic precursors containing a group 14 metal (Si, Ge, Sn) are advantageous when
labelling with radiohalogens [14, 24, 28]. Aryltrialkylmetal precursors facilitate the no-carrier-
added syntheses of radiolabelled arylhalides, described by the reaction mechanism in Figure
2.2:
X
A
A R3MA
X
MR3X
MR3
+ ++
-
-
1
-1
2
Figure 2.2: Proposed reaction mechanism of the halodemetallation using aryltrialkyl group
14 organometallic precursors, from Refs. [14, 24].
where X+–A− is a halonium-anion species, and M is silicon, germanium or tin. The alkyl
substituent R introduces a +I inductive eﬀect1 facilitating formation of the σ-complex inter-
mediate, while electron release by the -MR3 group decreases the possibility of competitive
halodeprotonations. An alternative and competing reaction mechanism goes via a radical-
ion-pair intermediate which collapses to the same σ-complex as shown in Figure 2.2 [29].
The carbon–metal bond dissociation energy and the covalent radius of the metal decrease
in the order Si < Ge < Sn, resulting in increased reaction rates and increased radiochemical
yields of the labelled arylhalides. While the radiochemical yield of a halodestannylation
is more or less unaﬀected by the labelling conditions, the eﬃciency of a halodesilylation
is inﬂuenced by the choice of solvent, oxidising agent, radionuclide, alkyl substituent R,
substituent(s) on the aromatic ring and pH [14, 30]. However, high radiochemical yields
may also be obtained for organosilicon compounds by optimising the labelling conditions. In
general, the use of silylated compounds have an advantage due to low toxicity and greater
chemical inertness during multi-step syntheses.
The required aryltrialkylmetal precursors can often be synthesised from lithiated organic
compounds. Radiohalogenated derivatives are produced when treating this precursor with a
radiohalogen using a mild oxidising agent.
1The term +I is used for functional groups being electron-donating relative to hydrogen.
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2.5 Structure determination of radioiodinated and astatinated
compounds
Structural assignment of a radioiodinated or astatinated compound can be predicted with
a good degree of certainty from the expected product of the corresponding non-radioactive
iodination [24, 28]. If the starting compound contains an activated aromatic ring (e.g. phenol
or aniline) and is treated with electrophilic radioiodine, the location of the radioactive label in
the product is a function of the +I and +M eﬀects2 of the aromatic substituent(s) [31, 32]. If
the compound is labelled by a substitution reaction, the label should appear in the place of the
leaving group (e.g. in iodine for bromine exchange, iododediazonisation or iododemetallation).
These structural assignments are made on the basis of analogy with non-radioactive re-
actions. However, reactions with no-carrier-added radionuclides may proceed very diﬀerently
due to the drastic change in ratios between reagents and the higher possibility of side eﬀects
produced by minor impurities in the reaction mixture. To analyse a radioiodinated or astati-
nated compound, its behaviour in various forms of chromatography is measured and compared
to the non-radiolabelled, iodinated compound. Chromatographic investigations are normally
performed by radio-HPLC [14, 28].
2The terms +I and -I describe ﬁeld eﬀects operating through space, solvent molecules or σ-bonds. The
terms +M and -M describe resonance eﬀects operating through π-electrons.
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Part II
MALIGNANT MELANOMA
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Chapter 3
Malignant melanoma
Malignant melanoma is the least common but most serious type of skin cancer. The incidence
is increasing rapidly, and the rates are doubled every 10–20 years in countries with white
populations [33]. Malignant melanoma is particularly common in Australia, New Zealand
and Scandinavia, and it is the most frequent cancer type for men (age 30–54) and young
women (age 15–29) in Norway [1, 34]. It is assumed that genetic susceptibility and occasional
exposure to high levels of ultraviolet radiation are the most important risk factors.
Human malignant melanoma represents a diﬃcult diagnostic and therapeutic challenge.
Survival is good provided early diagnosis and surgical resection of the primary tumor when
it is thin (<1mm) and has no nodal spread [33]. Surgery is often accompanied by radiation
therapy, chemotherapy or immunotherapy. However, malignant melanoma is characterised
by an early stage metastasis for which there is no eﬀective therapy; cancer chemotherapy
has failed, immunotherapy is virtually ineﬀective, and the majority of malignant melanomas
are resistant to radiation [35, 36]. Hence, targeted α-particle radiotherapy is an appealing
treatment modality for malignant melanoma.
The development of new melanoma-seeking agents for targeted radiotherapy warrants
an understanding of the biological and chemical properties characteristic for malignant
melanomas.
3.1 Origin and subtypes of malignant melanoma
Malignant melanoma is a cancer predominantly originating from pigment-producing cells
(nevi) in the skin. Less frequently, primary melanomas are also found in other pigmented
organs, e.g. eyes (uveal melanoma). The most common types of melanoma in the skin are
superﬁcial spreading melanoma, nodular melanoma, acral lentiginous melanoma and lentigo
maligna melanoma. The diﬀerent types of melanoma may or may not produce the pigment
17
18 Malignant melanoma
melanin. Amelanotic (non-pigmented) melanomas are rare and normally form cutaneous
nodules, while melanotic (pigmented) melanomas are more common and very malignant types
of cancer.
3.2 Melanogenesis
A biological uniqueness of most melanocytes and malignant melanomas is the biosynthesis
of melanin. Melanin is a dark pigment of complex polymer structure which is produced in
highly specialised intracellular organelles (melanosomes) in the melanocytes. Microgranules
of melanin are transferred to epithelial cells and form the pigment found in hair, epidermis,
eyes and in substantia nigra in the brain [37, 38].
The melanogenesis begins with the oxidation of tyrosine (1) by the enzyme tyrosinase
to give the activated compound dopaquinone (2). Dopaquinone can react via two diﬀerent
pathways to give the pigment polymers eumelanin and pheomelanin (Figure 3.1). The high
reactivity of ortho-quinone 2 chemically controls the early process of melanogenesis, and the
availability of the protein cysteine determines the ratio of eumelanin to pheomelanin [39–
41]. However, the melanogenesis is a complex process which is highly regulated by enzymes,
receptors and hormones under genetic control, and where the diﬀerent steps of the melanin
synthesis occur spontaneously dependent on the available concentrations of H+, metal ions,
reducing agents, thiols and oxygen [42].
Melanin and many melanin-related metabolites subserve several diﬀerent protective func-
tions, e.g. photoprotection, metal binding, scavenging of toxic oxygen radical species as well as
inﬂammatory and immune reactions [35, 37, 43, 44]. The process of melanogenesis, however,
represents a potential cellular hazard due to the formation of toxic ortho-quinone metabolites.
The ortho-quinones are highly reactive chemical species which undergo addition reactions with
glutathione (GSH), sulphydryl (SH) enzymes such as DNA polymerase and other proteins and
nucleic acids, causing cell inactivation or irreversible damages and cell death [44].
Most malignant melanomas show an enhanced biosynthesis of melanin and an increased
expression of tyrosinase. Thus, the chemistry of the melanogenesis may be exploited in the
development of new melanoma-seeking agents for diagnosis and therapy of this malignancy.
3.3 Sigma-receptors
Another feature of many malignant melanomas is the high expression of sigma-receptors. The
sigma (σ) receptor system consists of σ1- and σ2-receptors, and it is unique and diﬀerent from
other neurotransmitter and hormone receptor families [45]. Sigma-receptors are membrane-
bound proteins found in the central nervous system, liver, kidneys, lungs, gonads and ovaries,
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Figure 3.1: The synthesis of the melanin polymers eumelanin and pheomelanin, starting with
the tyrosinase oxidation of tyrosine (1) to give dopaquinone (2). Cys = cysteine, GSH =
glutathione, T = tyrosinase, M =metal ions, GTP = glutamyltranspeptidase, R = glutathione
reductase, P = peroxidase, TRP-1 = DHICA oxidase, TRP-2 = dopachrome tautomerase
(from Refs. [41, 43]).
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as well as in certain tumour tissues [46]. Thus, sigma-receptors have been proposed as targets
for selective binding of radiopharmaceuticals to cancers with an overexpression of sigma-
receptors, e.g. malignant melanoma, breast cancer and prostate cancer cells [46–52]. The
sigma-receptor system also provides a means to target amelanotic melanomas.
3.4 Radiolabelled melanoma-seeking agents
Random metastatic dissemination of melanoma requires a systemic treatment reaching all
melanoma cells. This may be achieved using melanoma-seeking compounds carrying radio-
nuclides with therapeutic properties (Sections 2.2–2.3).
Several melanoma-seeking radiopharmaceuticals have been developed (Table 3.1), but
none has so far achieved general clinical application in treatment of malignant melanomas
[53]. The main obstacles have been low selectivity for melanoma tissue and low sensitivity
in scintigraphic imaging detection of metastases. Thus, development of new radiolabelled
melanoma-seeking agents showing a selective uptake by the melanoma cells is critical.
There are a number of strategies for developing new melanoma-seeking agents. One
approach is based on the use of tyrosinase analogues designed to maximise the generation
of reactive ortho-quinones [44]. A selective method currently under development is based on
the release of a cytotoxic agent from a prodrug during melanogenesis (melanocyte-directed
enzyme-activated prodrug therapy, MDEPT) [44, 55–57]. The approaches most commonly
used for developing melanoma-seeking radiopharmaceuticals are based on the incorporation of
radiolabelled false precursors of melanin into the pigment polymers, or the use of radioactive
agents with a general aﬃnity for melanin [44]. Compounds that bind to melanin are numerous,
while compounds incorporated in pigment polymers during melanogenesis are exampliﬁed by
derivatives of phenylalanine [58, 59], cysteaminylphenol [36, 60–63] and thiouracil [64–66].
In this work focus has been on three diﬀerent classes of melanoma-seeking agents, having
diﬀerent uptake-mechanisms and, thus, diﬀerent abilities to target melanotic and amelanotic
melanomas. The background for selecting phenothiazine, cysteaminylphenol and benzamide
derivatives is presented in Sections 3.4.1–3.4.3.
3.4.1 Phenothiazine derivatives
In the 1950s it was found that the antipsychotic drug chlorpromazine (3) and sev-
eral other derivatives of phenothiazine (4) exhibited high aﬃnity for uveal pigment and
bonded intracellulary to melanin (Figure 3.2) [67]. Thus, several derivatives with the
phenothiazine structure were investigated as melanoma-seeking agents. The derivative
3,7-(dimethylamino)phenazathionium chloride (methylene blue, MTB 5) was particularly
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Table 3.1: Melanoma-seeking radiopharmaceuticals (from Refs. [53, 54]).
Uptake tests 32P-phosphate
3H-DOPA
Labelled drugs 131I-chloroquine
131I-chlorpromazine
Aspeciﬁc tracers 67Ga-citrate
57Co-bleomycin
111In-porphyrin
201Tl-chloride
99mTc-sestamibi
Metabolic tracers 123I-methyltyrosine
123I/131I-iodoquinoline derivatives
123I/131I-5-iodo-2-thiouracil derivatives
123I-iodobenzamide derivatives
123I-N -isopropyl-p-iodoamphetamine (IMP)
123I/131I-metaiodobenzylguanidine (MIBG)
18F-ﬂuorodeoxyglucose (FDG)
11C-methionine (MET)
Peptides 111In-pentetreotide
123I-vasoactive intestinal peptide (VIP)
111In-alpha-melanocyte stimulating hormone (MSH)
212Pb-DOTA-Re(Arg11)CCMSH
Monoclonal antibodies e.g. 131I-anti-p97 Mab/F(ab)2 fragments
99mTc-225.28 S F(ab)2 fragments
99mTc-NR-ML-05
111In-ZME-018
Immunoreactive agents Radiolabelled immunoreactive cells
99mTc-interleukin-2
99mTc-J001X
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interesting, showing very high aﬃnity for melanin and a strong charge transfer complex with
the melanin polymers resulting in a selective accumulation in pigmented melanomas [68, 69].
Link et al. have synthesised and evaluated radioiodinated and astatinated MTB-
derivatives (7 and 8, Figure 3.2) as potential radiopharmaceuticals for diagnosis and radio-
therapy of metastasised melanomas [68–75]. The reported results showed 95% inhibition of
tumour growth with 211At-MTB in pigmented melanoma models in vivo [68, 72] and good
sensitivity using 123I-MTB or 131I-MTB in scintigraphic detection of melanoma metastases in
patients [73, 75]. Hence, 211At-labelled MTB 8 and related thionin derivatives are promising
agents for selective and eﬃcient radiotherapy of pigmented melanoma and its metastases.
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Figure 3.2: Chemical structures of chlorpromazine (3) and phenothiazine (4), and a general
thionin structure representing MTB 5, methylene green 6 and the radiohalogenated MTB-
derivatives 7 and 8 previously investigated as melanoma-seeking agents.
3.4.2 Cysteaminylphenol derivatives
The enzyme tyrosinase is capable of oxidising a variety of natural and synthetic phenols,
giving rise to highly reactive and cytotoxic ortho-quinones which may be incorporated into
the melanin polymers [37, 76]. Thus, several phenolic compounds have been evaluated as
chemotherapeutic agents for malignant melanoma [77], of which the 4-S -substituted cyste-
aminylphenols 9 (Figure 3.3) have been particularly promising [36, 60, 62, 63, 78–83].
Jimbow et al. have been leading the development of new cysteaminylphenol derivatives,
evaluating their biochemistry, melanocytotoxicity and antimelanoma eﬀects in vitro and in
vivo [36, 60, 61, 78–80, 84–96]. Experiments have shown that melanin-incorporated 4-S -
cysteaminylphenol (4-S -CAP 10) inhibited tumour growth and increased the life span of mice
bearing the murine B16 melanoma model [36, 78, 84, 88, 90]. The N -acetylated derivative
N -acetyl-4-S -cysteaminylphenol (N -acetyl-4-S -CAP 11) has demonstrated similar or better
properties in vivo. Results with 11 have shown high melanocytotoxicity through depigmen-
tation of black hair follicles, promising antimelanoma eﬀects in murine B16F10 melanoma
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Figure 3.3: Examples of cysteaminylphenols investigated as melanoma-seeking agents.
colonies in mouse lungs and selective accumulation into murine B16 melanomas and pig-
mented human melanoma xenografts [36, 78, 84, 85, 87, 90]. Thus, it has been suggested
that N -acetyl-4-S -CAP 11 may be a valuable model for developing radiohalogenated agents
for early detection of metastasis, staging, follow-up and targeted radiotherapy of pigmented
malignant melanoma [86, 93].
3.4.3 Benzamide derivatives
Radioiodinated benzamide derivatives were ﬁrst studied as central nervous system D-2
dopamine receptor imaging agents [97]. By coincidence, their aﬃnity for melanocytes was
found by uveal uptake in mice [98]. The exact mechanism of benzamide accumulation in
melanocytes is unknown, however, uptake has been directly linked to the biosynthesis of
melanin [53, 99]. Radioiodinated benzamides also exhibit moderate to high aﬃnity for sigma-
receptors found in melanoma cell membranes [47, 49, 100, 101], but the signiﬁcance of this
contribution is debated [48, 99].
The melanin aﬃnity of numerous radioiodinated benzamides have been evaluated [48, 49,
98, 100, 102–106], and the N -(2-dialkylaminoalkyl)-4-[∗I]iodobenzamide derivatives 12 (Fig-
ure 3.4) have gained particular interest [98, 103, 107, 108]. Several derivatives of 12 have been
explored in detection of melanoma metastases using SPECT, and a phase II scintigraphic clin-
ical trial evaluating N -(2-diethylaminoethyl)-4-[123I]iodobenzamide ([123I]BZA 13) resulted in
a diagnostic sensitivity of 81% on a lesion basis and a speciﬁcity of 100% [107].
The introduction of an electrondonating phenyl substituent resulted in a series of
new benzamides, of which the radioiodinated derivative N -(2-diethylaminoethyl)-3-[∗I]iodo-
4-methoxybenzamide ([∗I]IMBA 14) showed superior melanoma/non-target tissue dose ratios
and improved contrast in scintigraphic images of pigmented and non-pigmented metastases
in patients [104, 109]. It has been suggested that uptake of 14 in non-pigmented melanomas
was due to the σ1-receptor aﬃnity of this compound (K i = 249 ± 17 nM) [48, 109]. Thus,
radiohalogenated derivatives of IMBA 14 may have a future in targeted radiotherapy of both
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melanotic and amelanotic malignant melanomas.
3.5 Aims of study
The objective of this study was to synthesise radioiodinated and astatinated melanoma-
seeking agents and evaluate their prospective use in diagnosis and targeted radiotherapy
of malignant melanoma and its metastases. The speciﬁc aims:
• Synthesise derivatives of MTB 5, N -acetyl-4-S -CAP 11 and
IMBA 14 labelled with 125I, 131I or 211At.
• Characterise in vivo stability and melanoma aﬃnity of the astatinated
and radioiodinated derivatives in melanoma-bearing mice.
Chapter 4
General methods
4.1 Radioactivity measurements
University of Oslo, Norway: Radioactivity measurements of radioiodinated and astatinated
compounds were carried out using the radioisotope dose calibrators CRC-127R (Capintec
Inc.) or VDC-304 (Veenstra Instrumenten bv.). The radioactivity content in excised organs
was measured with an 1480 WIZARD automatic gamma counter (Wallac) or using a 20%
Ge-detector measuring the polonium K X-rays of the 211At-daughter 211Po.
University of Washington, Seattle, USA: Radioactivity measurements of the radioiodinated
compounds were performed on a Capintec CRC-15R radioisotope calibrator (Capintec Inc.),
and radioactivity content in tissue samples was measured in a LKB 1282 automatic gamma
counter (Wallac).
4.2 Production and distillation of 211At
The 211At was produced at the Scanditronix MC-35 cyclotron, Oslo Cyclotron Laboratory,
University of Oslo, through bombardment of stable bismuth with 29MeV helium ions via the
209Bi(α, 2n)211At reaction. Targets were prepared by melting 209Bi metal into a circular cave
(diameter 25.4mm, depth 0.50mm) in the aluminium target backings (42 x 40 x 3mm), and
the bismuth was polished to a uniform 0.25mm thick layer prior to use. The target back-
side was water-cooled during irradiation (1–2 h), and the production eﬃciency was ∼35MBq
211At/μAh using a beam intensity of 5-10 μA [110].
The dry-distillation method was adopted from Lindegren et al. [111]. The still consisted
of a quartz tube inserted into a tubular oven. A custom-made teﬂon ﬁtting connected the
outlet of the quartz tube to the condensing unit which consisted of a PEEK-capillary loop
immersed into a bath of dry-ice and ethanol (-77 ◦C). Any volatile astatine escaping the
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condensation trap was forced through a gas wash-bottle containing aqueous Na2S2O5 and
traps with activated carbon.
The quartz tube was preheated for 1–2 h at 700–750 ◦C while ﬂushing with nitrogen. The
irradiated target was placed in a smaller quartz tube which rapidly was pushed into the center
of the still. Astatine vapourised in the still for 1–10min and condensed in the PEEK trap
when evacuating the system. The PEEK tubing was dismounted, and astatine was recovered
in 0.5mL methanol.
The 211At-distillation was conducted in a fume hood in a certiﬁcated type B laboratory
using two pairs of gloves, a fresh-air mask with carbon ﬁlters (RACAL Safety Limited, UK)
and a body dosimeter to monitor the radiation dose recieved from x-rays and γ-radiation.
The laboratory was continuously monitored for airborne α-particles by a high sensitivity
ion-chamber (LASK radon counter, Norway).
4.3 Chromatography
Analytical high-performance liquid chromatography (HPLC) is a very convenient method for
rapid puriﬁcation and isolation of small radiolabelled compounds. It is also an eﬃcient tool
for making preparations of radiolabelled agents for biological studies in vivo. If the mobile
phase consists of solvents which are non-toxic or easily removed, an isolated product is simply
dissolved in physiological phosphate buﬀered saline (20mM, pH 7.4) and sterile ﬁltered prior
to use.
One of the radio-HPLC systems applied in this work used a general method which was
applicable on a number of diﬀerent compounds (Chapter 6 and Paper IV). It was based
on separation by reversed phase radio-HPLC using a nonpolar C-18 surface modiﬁed silica
column (stationary phase) and a polar, linear gradient elution system consisting of aqueous
acidic acid and an increasing amount of methanol (mobile phase) [27]. The components
in the mixture were separated as a function of polarity; the more hydrophilic components
were eluted ﬁrst, while the more lipophilic components eluted under relatively high methanol
concentrations.
The other radio-HPLC system was a result of systematic studies involving ionic strength,
inorganic additives and pH, and was highly optimised for separation of the radiolabelled
benzamides [125I]IMBA 14b and [211At]AMBA 54 (Papers I–III) [112]. The system was
based on a PLRP-S 100 A˚ styrene-divinylbenzene column (stationary phase) and a polar
mobile phase run under isocratic conditions, giving a similar elution of molecules as in reversed
phase HPLC. However, the PLRP-S 100 A˚ column has the advantage of a broader pH stability
range (pH 1–14) and a higher surface area than a C-18 column, making it particularly well
suited for rapid separation of small molecules.
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Detailed speciﬁcations of radio-HPLC systems, instruments and detectors are found in
the respective papers (Papers I–IV).
4.4 Animals
Male and female athymic Balb/c nude mice (Balb/c nu/nu) were bred in the nude rodent
facility at the Norwegian Radium Hospital (Chapter 6 and Papers II–III) or the University
of Washington, Seattle, USA (Paper IV). The mice were kept under speciﬁc pathogen-
free conditions at constant temperature (24–26 ◦C) and humidity (30–50%). Sterilised food
and tap water were supplied ad libitum. Housing and all procedures involving animals were
performed according to protocols approved by the animal care and use committee at the Nor-
wegian Radium Hospital in compliance with the National Committee for Animal Experiment’s
guidelines on animal welfare [113, 114], or by the University of Washington’s Institutional
Animal Care and Use Committee in compliance with the NIH guidelines [115]. The animals
were anaesthetised as described in the respective papers (Papers II–IV).
4.5 Tumour models
The malignant melanoma xenograft lines used in this work were established in athymic mice
from metastases of patients admitted to the Norwegian Radium Hospital [116, 117]. The
melanoma line HHMSX is highly metastatic and melanotic (Chapter 6 and Paper II), while
the SESX line is an amelanotic melanoma model (Paper III).
4.6 Statistics
Data were expressed as mean values with standard deviations (SD) where n=3 or n=4.
Probability calculations were made by the two-tailed Student’s t-test with 5% signiﬁcance
limits.
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Chapter 5
Phenothiazine derivatives
5.1 Introduction
In this part of the study, the aim was to synthesise new radioiodinated and astatinated deriv-
atives of the promising phenothiazine derivative MTB 5. Previous studies have evaluated ∗I-
and 211At-labelled MTB-derivatives with the radiohalogen located on the thionin structure.
In this study, the idea was to connect the thionin structure to a chemical moiety carry-
ing the radioactive halogen. It was assumed that this strategy would result in derivatives
with the same melanoma-seeking behaviour as 5, and perhaps increase the melanoma up-
take due to an increased lipophilicity. Introduction of an appropriate leaving group should
facilitate radiolabelling reactions with ∗I and 211At. The MTB-derivative 3-dimethylamino-
7-methylaminophenothiazin-5-ylium chloride (Azure B 15, Figure 5.1) was chosen as starting
agent, facilitating regiospeciﬁc reactions at the secondary amine function.
S
N
NN
Cl
S
N
NN
Cl
S
N
NHN
Cl
SnR3
SnR3
15
Linker
Linker =
= aryl, vinyl
alkyl, ether
Figure 5.1: Chemical structure of Azure B 15 and general structures of the proposed target
molecules with and without a linker to the trialkylstannyl moiety, respectively.
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5.2 Results and discussion
In the work with Azure B 15 the main challenge was to synthesise a derivative incorporating
a trialkylstannyl function. The chosen strategy was to connect 15 to a chemical moiety
incorporating a trialkylstannyl leaving group, either directly or by using a linker. General
structures of the proposed target molecules are depicted in Figure 5.1.
Wilbur et al. have described and exploited the general applicability of the stannylated
aromatic activated ester Bu3SnAr-OTFP 16 for introduction of a chemical moiety with a
trialkylstannyl group through the formation of an amide bond [27, 118]. Thus, the stannylated
ester 16 was synthesised following the procedures depicted in Figure 5.2. The 4-iodobenzoic
acid (17) reacted with 2,3,5,6-tetraﬂuorophenol using EDC as a coupling agent to give iodide
18 (83%). The iodinated ester was converted into 16 (33%) using Bu6Sn2 in a palladium(0)-
catalysed stannylation. Reaction procedures are described in Ref. [118], and spectroscopic
data are summarised in Appendix C.
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Figure 5.2: Reaction scheme for synthesis of the iodinated activated ester 18 and the stan-
nylated derivative 16. Reagents and conditions: a) 2,3,5,6-tetraﬂuorophenol, EDC, EtOAc,
rt; b) Bu6Sn2, [Ph3P]4Pd, toluene, reﬂux.
Although reported in low yield, N -alkylation on the secondary amine function in
Azure B was assessed to be the shortest route to a derivatised analogue [119]. Thus, the
ﬁrst approach involved the introduction of a linker between 15 and the stannylated acti-
vated ester 16. Feigenbaum et al. have reported the reaction of N -tert -butoxycarbonyl-2-
chloroethylamine (19) and Azure B 15, giving the intermediate 20 which decomposed to
N -(2-aminoethyl)-Azure B 21 on heating [119]. Based on this, a synthetic approach aiming
at the stannylated Azure B derivative 22, and subsequently the radiohalogenated derivatives
23 and 24, was suggested as indicated in Figure 5.3.
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Figure 5.3: Retrosynthetic analysis of the 125I- and 211At-labelled Azure B derivatives 23 and
24 and the stannylated precursor 22.
The linker reagent 19 was synthesised in 84% yield from (BOC)2O and 2-chloroethylamine
hydrochloride following the procedures of Feigenbaum et al. [119]. However, the subsequent
reaction between 15 and 19 was in our hands not reproducible. Neither the reported product
N -(2-aminoethyl)-Azure B 21 nor the intermediate 20 were possible to identify.
Several experiments were conducted trying to connect potential linkers or other reactive
compounds to the secondary amine function of Azure B 15 (summarised in Figure 5.4), but
all product mixtures obtained were complex, and proper puriﬁcation and identiﬁcation of the
diﬀerent components were not achieved.
The second approach was based on direct incorporation of a trialkylstannyl moiety to
Azure B. It was suggested that 15 might react with the activated ester 16 via its secondary
amine function, giving the stannylated amide 25 and the radiohalogenated derivatives 26 and
27 (Figure 5.5). However, once more the product mixture obtained was very complex, and
the stannylated Azure B derivative 25 was not identiﬁed (Figure 5.6).
Later, another group working with Azure B experienced the same kind of problems as
those mentioned above [120]. Hence, the Azure B project was abandoned, and time did not
allow to pursue alternative routes to MTB-derivatives [121–123].
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Chapter 6
Cysteaminylphenol derivatives
6.1 Introduction
In this part of the study, focus has been on synthesising new radioiodinated and astatinated
derivatives of the promising cysteaminylphenol N -acetyl-4-S -CAP 11. The chosen strategy
was to synthesise halogenated derivatives of 11, and derivatives with the same biologically
active structure as 11 having the halogen label located on a more distant chemical moiety.
It was assumed that all these derivatives would show similar melanoma-seeking behaviour as
11. The latter group would probably show higher in vivo stability, as well as higher tumour
accumulation due to a higher lipophilicity. However, rapid renal excretion and clearance
should be expected for all cysteaminylphenol derivatives [124, 125]. The radiohalogenated
derivatives 28b, 29, 30b and 31 were chosen as target molecules (Figure 6.1).
It has been postulated that phenols incorporating a sulphur atom are better substrates for
tyrosinase, giving rise to an increased accumulation in pigmented tissues [60, 84]. Hence, the
radioiodinated tyramine homologues 32b and 33b,c (Figure 6.1) were pursued for comparison
with the corresponding cysteaminylphenol derivatives in a pigmented melanoma model in vivo.
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Figure 6.1: Chemical structures of the proposed target molecules 28b–33c.
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6.2 Chemistry
6.2.1 Synthesis
Synthetic eﬀorts toward N -[2-(4-hydroxy-3-tributylstannyl-phenylsulphanyl)-
ethyl]acetamide (34) and its iodo derivative 28a
In the study of melanoma-seeking cysteaminylphenol derivatives, the ﬁrst target molecule
chosen was the cysteaminylphenol N -[2-(4-hydroxy-3-iodo-phenylsulphanyl)ethyl]acetamide
(28a) and its radiohalogenated analogues 28b and 29 (Figure 6.2). A synthetic approach
to 28b and 29 was suggested to proceed via the stannylated precursor N -[2-(4-hydroxy-3-
tributylstannyl-phenylsulphanyl)ethyl]acetamide (34) as depicted in Figure 6.2. The stan-
nylated precursor might be synthesised by standard stannylation reactions from the corre-
sponding ortho-halogenated cysteaminylphenols 28a or 35, which should be obtained by
direct halogenation of 11. Both cysteaminylphenols N -acetyl-4-S -CAP 11 and 4-S -CAP 10
would be synthesised following literature procedures [60, 93].
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Figure 6.2: First retrosynthetic analysis of the stannylated precursor 34.
Miura et al. have reported the synthesis of 10 by reﬂuxing phenol and cystamine di-
hydrochloride in 47% HBr [60]. Thus, cysteaminylphenol 10 was synthesised accordingly,
followed by N,O-acetylation and subsequent saponiﬁcation of the phenolic acetyl group to
give 11 (Figure 6.3) [93]. However, the chemical yields of 10 and 11 were low (∼10%), and
subsequent direct bromination or iodination of these compounds were unsuccessful.
The next strategy suggested direct halogenation of 4-mercaptophenol (36) producing the
dihalogenated disulphides 37 and 38, which may be reduced to two thiols and converted into
28a or 35 via the Wehrmeister reaction [126, 127]. However, analysis of the reaction product
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Figure 6.3: Literature procedure for synthesising the cysteaminylphenols 10 and 11 (Refs.
[60, 93]). Reagents and conditions: a) cystamine dihydrochloride, 47% HBr, reﬂux; b) i)
Ac2O, pyridine, rt; ii) NH3, MeOH, rt.
revealed close to quantitative yields of the disulphide 39 (Figure 6.4). All attempts in intro-
ducing halogen in the aromatic ring gave very complex product mixtures and were therefore
rejected. It was assumed that the halogenations did not work out as expected due to the
sulphur atom interfering with the halogenation reactions. Sulphur is easily oxidised and most
sulphur ethers are unsuitable as protecting groups if exposed to iodine [128]. Consequently,
the synthetic approach involving direct halogenation of sulphur compounds was abandoned.
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Figure 6.4: Halogenation of 4-mercaptophenol (36) gave the disulphide 39 in close to quan-
titative yields. The halogenated derivatives 37 and 38 were not obtained. Reagents and
conditions: a) I2, Et2O, H2O, rt; b) Br2, Et2O, H2O, rt.
A new strategy was outlined using an ortho-halogenated phenol which could react with
a suitable sulphur derivative in the para-position (Figure 6.5). The method of Miura et al.
should give the ortho-halogenated derivative of 10, but the prospects of low yields and a
mixture of isomers made this approach less appealing [60, 86]. However, Kita et al. have
reported the para-selective thiocyanation of various types of phenols in good to excellent
yields using PhICl2 and Pb(SCN)2 [129, 130]. Thus, PhICl2 was synthesised [131, 132], and
the two 2-halophenols 40 and 41 were subjected to thiocyanation using the in situ generated
[PhI(SCN)2] reagent (Figure 6.6) giving the corresponding thiocyanates 42 and 43 in low
chemical yields (7–27%). Increased chemical yields of 42 and 43 (>50%) were obtained in
thiocyanations of the respective halogenated phenols 40 and 41 using NH4SCN and Br2 in
glacial acetic acid [133].
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Figure 6.5: Second retrosynthetic analysis of the stannylated precursor 34.
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Figure 6.6: Reaction scheme for thiocyanation of 40 and 41 using PhICl2 and Pb(SCN)2
yielding 42 and 43, respectively (from Refs. [129, 131].)
It was assumed that a subsequent alkaline hydrolysis of the halogenated thiocyanates 42
and 43 would give the corresponding thiols 44 and 45 [134, 135]. Thus, thiocyanates 42
and 43 were allowed to react with aqueous NaOH in MeOH, but under these conditions the
corresponding methylthiolethers 2-halo-4-methylsulphanylphenol emerged. However, chang-
ing the solvent to aqueous Na2CO3 resulted in the dihalogenated disulphides 37 and 38 in
high chemical yields (80–95%). Subsequent NaBH4 reductions of 37 and 38 aiming at the
corresponding thiols 44 and 45 were ineﬃcient, however treating 37 and 38 with Ph3P in
the presence of water rapidly gave 44 and 45 in high yields [32, 134]. To avoid rapid oxida-
tion of the thiols in air, the crude product containing 44 or 45 was immediately reﬂuxed in
2-methyl-2-oxazoline and xylene according to the Wehrmeister reaction [126, 127] to give the
corresponding halogenated cysteaminylphenols 28a or 35 in >56% yield.
Great eﬀorts were made in stannylating the halogenated cysteaminylphenols 28a and
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35, however, both palladium(0)-catalysed stannylations with R6Sn2/(Ph3P)4Pd (R=Me, Bu)
and reactions using n-BuLi/Bu3SnCl were discouraging (Figure 6.7). The stannylated cyste-
aminylphenol 34 was not identiﬁed in the palladium(0)-catalysed reactions. Similar results
were obtained with the O-acetylated analogue 46 (Figure 6.7). These results were proba-
bly due to inhibition by the sulphur atom [136]. In the n-BuLi/Bu3SnCl reactions a rapid
hydrolysis was observed, mainly yielding N -acetyl-4-S -CAP 11 and minimal amounts of 34
(∼6%). Hydrogen for iodine substitution was also observed when trying to obtain a precursor
incorporating the less reactive trimethylsilyl leaving group (47, Figure 6.7). Hydrolysis was
veriﬁed by 1H-NMR and 13C-NMR when quenching the reaction with D2O gave no incor-
poration of deuterium in the ortho-position. Consequently, it was assumed that hydrolysis
was caused by the slightly acidic amide N -H hydrogen reacting with the 3-lithio intermedi-
ate giving N -acetyl-4-S -CAP 11. Thus, protection of the amide function using CH3MgBr
or (BOC)2O followed by lithiation, stannylation and deprotection steps might improve the
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Figure 6.7: Summary of diﬀerent reactions performed in the eﬀorts of synthesising the stannyl-
ated precursor 34 or an analogue. Reagents and conditions: a) (Ph3P)4Pd, Bu6Sn2, toluene,
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Figure 6.8: Reaction scheme for synthesis of the stannylated precursor 34 and the 125I- and
211At-labelled cysteaminylphenols 28b and 29, respectively. Reagents and conditions: a)
NH4SCN, Br2, glacial acetic acid, 10 ◦C; b) NaOH(aq), Na2CO3(aq), 35 ◦C; c) Ph3P, dioxane,
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THF, -78 ◦C; iii) sat. NH4Cl(aq), rt; f) Na125I or 211At, NCS, AcOH, MeOH, rt.
yield of 34. Protection of the phenolic hydroxyl group may also be considered. However,
it was decided to proceed with the available amount of 34 to evaluate in vivo stability and
biological properties of 28b and 29, as such experiments would be decisive for the need of
more precursor 34.
The ﬁnal synthetic route to precursor 34 and its radiohalogenated derivatives 28b and 29
is depicted in Figure 6.8. All reactions were ﬁrst established using the brominated derivatives
(spectroscopic data are summarised in Appendix C). In general, the brominated derivatives
were obtained in higher chemical yields compared to their iodinated analogues. However,
the non-radioactive iodide 28a was required as a reference compound in the radio-HPLC
characterisations of 28b and 29. Detailed descriptions of reactions and spectroscopic data of
the iodinated derivatives leading to precursor 34 are described in Paper IV.
Synthesis of N -[2-(4-hydroxy-phenylsulphanyl)ethyl]-4-tributylstannylbenzamide
(48) and its iodo derivative 30a
The synthesis of N -[2-(4-hydroxy-phenylsulphanyl)ethyl]-4-tributylstannylbenzamide (48)
and its iodo derivative 30a is depicted in Figure 6.9. The cysteaminylphenol 11 was syn-
thesised via the Wehrmeister reaction. The 4-mercaptophenol 36 was reﬂuxed in 2-methyl-
2-oxazoline to give acetamide 11, followed by a reduction to the corresponding amine 10
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Figure 6.9: Reaction scheme for synthesis of the stannylated precursor 48 and the 125I- and
211At-labelled cysteaminylphenols 30b and 31, respectively. Reagents and conditions: a) 2-
methyl-2-oxazoline, 130–160 ◦C; b) conc. HCl(aq), reﬂux; c) Bu3SnAr-OTFP 16, Et3N, DMF,
rt; d) IAr-OTFP 18, Et3N, DMF, rt; e) Na125I or 211At, NCS, AcOH, MeOH rt.
according to the procedures of Padgette et al. and Prezioso et al. [137, 138]. The aromatic
activated esters 16 and 18 reacted with the amine 10 to give the corresponding benzamides
48 and 30a in 34% and 51% total yields, respectively. Detailed descriptions of reactions and
spectroscopic data of the compounds are found in Paper IV.
Synthesis of N -[2-(4-hydroxyphenyl)ethyl]acetamide (49) and its iodo derivative
32a
The synthesis of N -[2-(4-hydroxyphenyl)ethyl]acetamide (49) and the iodinated derivative
32a is outlined in Figure 6.10. Tyramine 50 was converted into the ester amide 51 through
a N,O-acetylation, followed by a saponiﬁcation of the phenolic acetyl group to give amide
49. The amide 49 underwent direct electrophilic iodination yielding 32a using a general
labelling procedure. The non-radioactive iodide 32a was identiﬁed by LC-MS analysis of the
reaction mixture, and the HPLC retention time was used to identify the peak of the radio-
iodinated derivative 32b on radio-HPLC. Reactions and spectroscopic data of the compounds
are described in detail in Paper IV.
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Figure 6.10: Reaction scheme for synthesis of the 131I-labelled tyramine derivative 32b.
Reagents and conditions: a) Ac2O, 4-DMAP, pyridine, rt; b) NaHCO3(aq), MeOH, rt; c)
KI or Na131I, NCS, AcOH, MeOH, rt.
Synthesis of N -[2-(4-hydroxyphenyl)ethyl]-4-tributylstannylbenzamide (52) and
its iodo derivative 33a
The synthesis of N -[2-(4-hydroxyphenyl)ethyl]-4-tributylstannylbenzamide (52) and its iodo
derivative 33a is outlined in Figure 6.11. Precursor 52 and the iodinated derivative 33a were
synthesised using the methods of Wilbur et al. [118]. Tyramine 50 reacted with the aromatic
activated esters 16 and 18 to give the corresponding benzamides 52 and 33a in 63% and
58% yields, respectively. Detailed descriptions of the reactions and spectroscopic data of the
compounds are found in Paper IV.
OH
NH2
OH
H
N
O
X
OH
H
N
O
SnBu3
a
b
c
50
52
33a: X = I
33b: X = 125I
33c: X = 131I
53: X = 211At
Figure 6.11: Reaction scheme for synthesis of the stannylated precursor 52 and the 125I-,
131I- and 211At-labelled tyramine derivatives 33b, 33c and 53. Reagents and conditions: a)
Bu3SnAr-OTFP 16, Et3N, DMF, rt; b) IAr-OTFP 18, Et3N, DMF, rt; c) Na125I or Na131I or
211At, NCS, AcOH, MeOH, rt.
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6.2.2 Radiolabelling and puriﬁcation
Precursors 34, 48, 49 and 52 were radiohalogenated using the general labelling procedure
described in Paper IV (with minor modiﬁcations for 211At). Radiohalogenations with ∗X =
125I, 131I or 211At were performed under acidic conditions using NCS as oxidising agent in a
solution of MeOH/AcOH (9:1) for 5–30min (Figures 6.8–6.11). The radioiodinated derivatives
28b, 30b, 32b and 33b,c were obtained in 80–95% integrated radiochemical yields, while
the yields of the astatinated derivatives 29, 31 and 53 were in the range 50–90% (Table 6.1).
Compound 49 was radiolabelled via a direct electrophilic iodination to give 32b. Hence, an
astatinated derivative of compound 49 was not obtained (Section 2.4.1).
The radiohalogenated products were identiﬁed on radio-HPLC by co-injection with the
corresponding non-radioactive iodinated derivative. Radio-HPLC puriﬁcation and isola-
tion gave the radiohalogenated products in 30–85% isolated radiochemical yields. Isolated
products were concentrated in vacuo, transferred into PBS, pH adjusted and sterile ﬁltered
prior to use (Paper IV). Preparations were made by combining two or three compounds
labelled with diﬀerent radionuclides in each biodistribution study.
Table 6.1: Integrated radiochemical yields estimated by radio-HPLC.
Radiohalogenated compound Integrated radio-
chemical yield
N -[2-(4-hydroxy-3-[125I]iodo-phenylsulphanyl)ethyl]acetamide 28b 80 %
N -[2-(4-hydroxy-3-[211At]astato-phenylsulphanyl)ethyl]acetamide 29 50 %
N -[2-(4-hydroxy-phenylsulphanyl)ethyl]-4-[125I]iodobenzamide 30b 80 %
N -[2-(4-hydroxy-phenylsulphanyl)ethyl]-4-[211At]astatobenzamide 31 70 %
N -[2-(4-hydroxy-3-[131I]iodophenyl)ethyl]acetamide 32b 90 %
N -[2-(4-hydroxyphenyl)ethyl]-4-[125I]iodobenzamide 33b 95 %
N -[2-(4-hydroxyphenyl)ethyl]-4-[131I]iodobenzamide 33c 95 %
N -[2-(4-hydroxyphenyl)ethyl]-4-[211At]astatobenzamide 53 90 %
6.3 Biology
6.3.1 Preliminary biodistribution studies
Preliminary biodistribution studies were were conducted at the University of Washington,
Seattle, USA (Paper IV). One group of normal Balb/c nude mice (male) were injected the
radioiodinated acetamides 28b and 32b, and another group were injected the radioiodinated
benzamides 30b and 33c. The injection volume contained approximately 370 kBq of each
radioiodinated compound. Animals were sacriﬁced 0.5 h, 2 h and 6 h post-injection while
under xylazine/ketamine anesthesia.
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6.3.2 Biodistribution studies in the HHMSX model
Biodistribution studies in a melanoma model were conducted at the Norwegian Radium Hos-
pital using experimental procedures identical to those described in Paper II. Animal studies
were carried out in Balb/c nude mice (male) bearing the malignant melanoma xenograft
HHMSX (melanotic). The mice (weight 28–37 g) were injected 100 μL of preparation I) 28b
and 29, II) 30b and 31 or III) 32b, 33b and 53 into a lateral tail vein (Table 6.2). At
0.5 h, 2 h, 6 h and 16 h post-injection, four animals were sacriﬁced by cardiectomy while under
hypnorm/dormicum anesthesia.
Table 6.2: Properties of radiolabelled cysteaminylphenols and tyramine derivatives studied
in Balb/c nude mice bearing the HHMSX melanoma model.
Preparation Radiohalogenated Activity injected/ tR
compound 100 μL
I 28b 130 kBq 11.5 min
I 29 110 kBq 12.9 min
II 30b 100 kBq 14.3 min
II 31 160 kBq 16.6 min
III 32b 80 kBq 9.4 min
III 33b 80 kBq 13.9 min
III 53 230 kBq 14.6 min
6.4 Results and discussion
Preliminary biodistribution studies
Preliminary biodistribution studies were performed with the 125I- or 131I-labelled derivatives
28b, 30b, 32b and 33c in normal Balb/c nude mice. The studies were conducted to evaluate
the in vivo stability of the radioiodinated compounds, as well as the distribution and clearance
from non-target tissues (Paper IV). The results indicated that all the radioiodinated deriva-
tives showed high stability to enzymatic deiodination in vivo. Both the cysteaminylphenols
28b and 30b and the corresponding tyramine derivatives 32b and 33c seemed to undergo
a very fast metabolism and renal excretion, resulting in low concentrations of radioactivity
in non-target tissues 6 h post-injection. Biodistribution data are presented in Tables D.1 and
D.2 (Appendix D), and the results are summarised in Paper IV.
Biodistribution studies in the melanotic melanoma model HHMSX
The prospects of high tumour to non-target tissue dose ratios for the radioiodinated derivatives
28b, 30b, 32b and 33c encouraged a new series of biodistribution studies in mice bearing the
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human malignant melanoma xenograft HHMSX. The astatinated derivatives 29, 31 and 53
were included in the studies to evaluate their potential in targeted radiotherapy of malignant
melanoma. Biodistribution data are presented in Tables D.3–D.6 (Appendix D), and the
results are summarised in Figures 6.12 and 6.13.
Figure 6.12: Results of the biodistribution studies of 28b, 30b, 32b and 33b in Balb/c
nude mice bearing the HHMSX melanoma model. Gastric and intestinal values include their
contents.
Generally, the concentration of radioiodine (% ID/g) measured in all organs and tissues
were signiﬁcantly lower than the values reported for 28b, 30b and 32b in the preliminary
biodistribution studies. This observation was not expected since the use of internal standards
should have eliminated diﬀerences in the detection instruments, as well as in the diﬀerent
amounts of radioactivity injected in the mice. However, the results revealed the same trends
in the distribution of the radioiodinated compounds between diﬀerent organs, producing
44 Cysteaminylphenol derivatives
proportionally similar organ-to-organ uptake ratios as reported in Paper IV. Consequently,
the new results were compared and evaluated strictly in terms of uptake ratios.
Free radioiodide is primarily localised in thyroid and stomach, and preferentially in thy-
roid, yielding thyroid-to-stomach uptake ratios above unity [27]. In these studies the uptake
in thyroid was signiﬁcantly lower than in stomach (P<0.05), verifying the in vivo stability
towards dehalogenation of 28b, 30b, 32b and 33b,c reported in Paper IV. Similarly, the
trends of very rapid renal excretion and clearance were conﬁrmed (Tables D.3–D.6).
The results did not indicate any speciﬁc accumulation of 28b, 30b, 32b or 33b in the
melanotic melanoma model HHMSX, giving approximately the same amount of detected
radioiodine in tumour as in blood and healthy skin (Table 6.3). The only compounds show-
ing steadily increasing tumour-to-blood and tumour-to-muscle dose ratios were 30b and 32b,
however, the values were low and the potential tumour-accumulation over time was not con-
vincing. Given these results, the postulated diﬀerence in melanocyte incorporation between
cysteaminylphenols and tyramine derivatives could neither be demonstrated nor evaluated in
this study using the HHMSX melanoma model.
Table 6.3: Melanoma/non-target tissue dose ratios of 28b, 30b, 32b and 33b in Balb/c nude
mice bearing the melanotic melanoma xenograft HHMSX.
28b 30b 32b 33b 29 31 53
Tumour/Blood
0.5 h 0.6 0.7 1.0 0.8 1.2 0.7 1.4
2 h 0.6 0.9 1.0 0.5 1.9 3.1 1.7
6 h 0.9 1.0 1.7 0.8 2.3 2.8 2.2
16 h 1.3 2.5 3.5 0.7 2.0 NA 1.8
Tumour/Muscle
0.5 h 1.5 2.4 1.9 2.9 2.8 2.5 3.3
2 h 2.3 2.8 4.1 3.0 3.6 5.3 3.6
6 h 2.0 3.8 NA 2.4 3.9 5.3 4.2
16 h 2.0 5.0 NA 1.7 4.6 NA 2.8
Tumour/Skin
0.5 h 0.8 0.7 1.2 1.0 0.6 0.5 0.7
2 h 0.6 1.1 1.1 0.6 0.8 1.1 0.8
6 h 0.3 0.8 0.6 0.5 0.8 0.6 0.7
16 h 0.4 0.6 1.2 0.5 0.6 NA 0.4
NA = not applicable (% ID/g muscle ∼0.)
The best method for evaluating in vivo stability of astatinated compounds is by performing
co-injected dual label experiments with radioiodine [27]. Radioiodinated and astatinated
compounds that are stable to dehalogenation may show very similar distribution in vivo.
However, free astatide will primarily localise in lungs, spleen, thyroid and stomach while
free radioiodide will accumulate in thyroid and stomach. Thus, large diﬀerences between the
concentrations of the radiohalogens in these tissues are good indicators of in vivo instability of
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astatinated compounds. In the HHMSX biodistribution studies of the astatinated derivatives
29, 31 and 53, high amounts of 211At were detected in lungs, spleen, thyroid and stomach
(Figure 6.13). This result indicated that most, if not all, of the detected 211At was present as
free astatide. Hence, it was concluded that the astatinated derivatives 29, 31 and 53 were
unstable in vivo.
Figure 6.13: Results of the biodistribution studies of 29, 31 and 53 in Balb/c nude mice
bearing the HHMSX melanoma model. Gastric and intestinal values include their contents.
Given these results, the amounts of intact 29, 31 and 53 undergoing tumour-accumulation
would be low, and it is impossible to distinguish between tumour uptake of the astatinated
cysteaminylphenol derivatives and of the free astatide. Consequently, the HHMSX tumour
uptake ratios of 29, 31 and 53 could not be further evaluated. However, the tumour/non-
target tissue dose ratios have been included in Table 6.3 for comparison.
The carbon–astatine bond is weaker than the carbon–iodine bond. Thus, a situation
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showing high in vivo stability of radioiodinated compounds and extensive deastatination of
the corresponding astatinated analogues often occur. A diﬀerent chemical approach yielding
more stable astatine-compounds might involve the use of carborane-cages giving astatinated
boron cage molecules [16].
Conclusion
Biodistribution data of 28b, 29, 30b, 31, 32b, 33b and 53 were analysed using a coarse
method based on organ uptake ratios. Nevertheless, it was revealed that these radiohalo-
genated cysteaminylphenol and tyramine derivatives did not possess the biological properties
required for diagnostic and therapeutic radiopharmaceuticals for malignant melanoma. The
astatinated compounds 29, 31 and 53 were unstable to deiodinase enzymes in vivo. The
radioiodinated compounds 28b, 30b, 32b and 33b showed high in vivo stability, but biodis-
tribution studies did not indicate tumour accumulation in the HHMSX melanoma model.
Thus, a new series of HHMSX biodistribution studies with these compounds to obtain a more
detailed analysis of the organ uptake values (% ID/g), were not considered justiﬁed.
Chapter 7
Benzamide derivatives
7.1 Introduction
In the work with benzamide derivatives the aim was to synthesise an astatinated analogue of
the promising benzamide [∗I]IMBA 14. It was suggested that the astatinated analogue would
show a melanoma-seeking behaviour and a sigma-receptor aﬃnity similar to 14, facilitating
targeted α-particle radiotherapy of malignant melanoma and its metastases.
In the literature, [∗I]IMBA 14 was synthesised using the Tl(TFA)3/I− method [104, 109,
139]. Generally, electrophilic aromatic thallations with Tl(TFA)3 in TFA are rarely used in
synthetic organic chemistry due to limited versatility and harsh reaction conditions. The
reaction mechanism is complex [32], and it is diﬃcult to control yields and isomeric products
of the in situ thallation [14, 24]. It is also a matter of controversy whether the halodethallation
may give the radioiodinated or astatinated products without the addition of a carrier [14, 24,
104, 109, 112, 140, 141].
Thus, an improved method for synthesising no-carrier-added radioiodinated and astati-
nated derivatives of 14 was required. The chosen strategy was to synthesise a stannylated
precursor of 14, facilitating regiospeciﬁc astatination to give the target molecule N -(2-diethyl-
aminoethyl)-3-[211At]astato-4-methoxybenzamide ([211At]AMBA 54, Figure 7.1).
7.2 Chemistry
7.2.1 Synthesis of N -(2-diethylaminoethyl)-3-(tri-n-butylstannyl)-
4-methoxybenzamide (55) and its iodo derivative 14a
The synthesis of the stannylated precursor N -(2-diethylaminoethyl)-3-(tri-n-butylstannyl)-
4-methoxybenzamide (55) and its iodo derivative 14a is depicted in Figure 7.1. The
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method was based on the ATE-synthesis described by Zalutsky et al. [142]. The
3-bromo-4-methoxybenzoic acid (56) was converted into its stannylated derivative 57 using
n-BuLi/Bu3SnCl. The benzoic acid 57 reacted with N -hydroxysuccinimide using N,N’ -
dicyclohexylcarbodiimide as a coupling reagent. The resulting activated ester 58 reacted
with 2-(diethylamino)ethylamine to give the stannylated benzamide 55 in 65% total chemi-
cal yield [112]. Detailed descriptions of reactions and spectroscopic data are found in Papers
I–II.
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Figure 7.1: Reaction scheme for synthesis of the stannylated precursor 55 and the radio-
labelled products [125I]IMBA 14b and [211At]AMBA 54. Reagents and conditions: a) i)
n-BuLi, THF, -78 ◦C; ii) Bu3SnCl, THF, -78 ◦C; iii) sat. NH4Cl(aq), rt; b) NHS, DCC, THF,
rt; c) 2-(diethylamino)ethylamine, CHCl3, rt; d) KI or Na125I or 211At, NCS, AcOH, MeOH,
rt.
7.2.2 Radiolabelling and puriﬁcation
Precursor 55 was radiohalogenated with ∗X = 125I or 211At using the labelling procedure de-
scribed in Papers I–II. Radiohalogenations were performed under acidic conditions using NCS
as oxidising agent in a solution of MeOH/AcOH (9:1) for 5–15min (Figure 7.1). Radio-HPLC
analysis showed [125I]IMBA 14b and [211At]AMBA 54 in 70–90% integrated radiochemical
yields. The products 14b and 54 were obtained in 55–60% isolated yields and ≥99% radio-
chemical purities [112]. The radiohalogenated benzamides were identiﬁed on radio-HPLC
by co-elution with the non-radioactive IMBA 14a. The isolated products were concentrated
in vacuo, dissolved in PBS, pH adjusted and sterile ﬁltered prior to use. Preparations for
biodistribution studies were made by combining solutions of 14b and 54 (Papers II–III).
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7.3.1 Biodistribution studies in the HHMSX model
Biodistribution studies were conducted at the Norwegian Radium Hospital using Balb/c nude
mice (male) bearing the melanotic melanoma xenograft HHMSX (Paper II). The animals
were injected 100 μL of a preparation of 14b (120 kBq) and 54 (430 kBq) in PBS. At 0.5 h,
2 h, 6 h and 16 h post-injection, three or four animals were sacriﬁced by cardiectomy while
under hypnorm/dormicum anesthesia.
7.3.2 Biodistribution studies in the SESX model
Biodistribution studies were conducted at the Norwegian Radium Hospital using Balb/c nude
mice (female) bearing the amelanotic melanoma xenograft SESX (Paper III). The animals
were injected 100 μL of a preparation of 14b (110 kBq) and 54 (450 kBq) in PBS. At 1 h, 4 h
and 16 h post-injection, three animals were killed by cervical dislocation [112].
7.4 Pharmacology
Pharmacology experiments were performed at the Department of Pharmacology, University
of Oslo. Preparations of SESX cell membranes for radioligand binding assays were made from
frozen tumour nodules as described in Paper III. To avoid complications with necrotic tissue,
cells were harvested from small tumours weighing 0.1–0.25 g. Radioligand binding assays
were performed with the selective σ1-receptor ligand [3H]-(+)-pentazocine in the absence
(total binding) or presence (non-speciﬁc binding) of haloperidol. The corresponding K d and
Bmax values were determined by analysis of speciﬁc binding data (Paper III). Pharmacology
experiments with HHMSX cell membranes were conducted for comparison, and the results
are summarised in Table 7.1.
Table 7.1: Results of pharmacological binding studies of the SESX and HHMSX melanoma
models. Bmax is the total number of σ1-receptors and K d is the equilibrium dissociation
constant.
Melanoma model Bmax (mol/mg protein) K d (nM)
SESX (1.5 ± 0.3) × 10−12 6.8 ± 0.9
HHMSX (242 ± 12) × 10−15 16.3 ± 0.3
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Figure 7.2: Results of the biodistribution studies of 14b and 54 in Balb/c nude mice bearing
the melanoma xenografts HHMSX (left) and SESX (right). Gastric and intestinal values
include their contents.
7.5 Results and discussion
Paired label biodistribution studies of the benzamides [125I]IMBA 14b and [211At]AMBA 54
were conducted in Balb/c nude mice bearing the melanotic melanoma xenograft HHMSX
(Paper II) or the amelanotic melanoma xenograft SESX (Paper III). The studies were
performed to evaluate in vivo stability of the astatinated benzamide 54, distribution and
clearance from non-target tissues, as well as uptake of 14b and 54 in pigmented and non-
pigmented melanomas. Biodistribution data are presented in Tables D.7 and D.8 (Appendix
D), and the results are summarised in Figure 7.2.
Both studies showed low uptake values of 211At in the neck and other tissues with aﬃnity
for free astatide. In the HHMSX study the thyroid gland was excised and the accumu-
lated radioactivity was measured, yielding moderate and steadily decreasing uptake values
of 211At (mean values from 4.9 % ID/g to 1.1 % ID/g). In contrast, enzymatic deastatin-
ation should give increasing uptake values in thyroid and other non-target tissues during the
ﬁrst 4 h post-injection [27]. Consequently, it was assumed that the 211At detected in lungs,
spleen, stomach and thyroid primarily was due to uptake of unmetabolised 54 and other
211At-labelled metabolites rather than free astatide. Although some decomposition of 54
might have taken place, no extensive enzymatic deastatination in vivo was observed.
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Table 7.2: Melanoma/non-target tissue dose ratios of 14b and 54 in Balb/c nude mice bearing
the melanotic melanoma xenograft HHMSX and the amelanotic melanoma xenograft SESX.
HHMSX SESX
0.5 h 2 h 6 h 16 h 1 h 4 h 16 h
Tumour/Blood
14b 1.6 3.6 10.7 12.0 2.0 9.4 8.6
54 0.9 1.5 0.8 1.4 2.6 2.8 1.5
Tumour/Muscle
14b 2.3 10.0 50.0 30.0 5.0 23.5 NA
54 1.5 5.0 4.4 4.0 3.3 3.3 3.8
Tumour/Skin
14b 1.1 2.5 5.4 8.6 0.9 5.2 4.3
54 0.4 0.5 0.3 0.4 0.8 0.9 0.5
NA = not applicable (% ID/g muscle ∼0.)
Tumour accumulation in the melanotic melanoma model HHMSX
The tumour uptake mechanism of the benzamides 14b and 54 in the pigmented melanoma
model HHMSX should go via the melanin synthesis and the σ1-receptors expressed on the
HHMSX cell membranes. However, pharmacology experiments revealed a very low density of
σ1-receptors on these cell membranes (Table 7.1), indicating that the melanin synthesis will
be the primary uptake mechanism of 14b and 54 in this melanoma model.
Results from the biodistribution studies in mice bearing the melanotic melanoma model
HHMSX showed slightly higher tumour uptake values for 54 than 14b (0.9 % ID/g and
0.5 % ID/g after 2 h, respectively). However, the iodinated benzamide 14b demonstrated
faster clearance from non-target tissues which gave rise to higher melanoma/non-target tissue
dose ratios (Table 7.2). Thus, the proposed diagnostic value of the 123I-labelled IMBA in
scintigraphic imaging of malignant melanomas was conﬁrmed in this study [48, 104, 109].
The melanoma/non-target tissue dose ratios also indicated a small tumour accumulation of
54, but the low tumour uptake combined with a slow clearance from most non-target tissues
suggested limited prospects of using 54 in targeted radiotherapy of malignant melanomas
(Paper II).
However, it is diﬃcult to evaluate the melanoma-seeking properties of 14b and 54 using
the results obtained with the HHMSX melanoma xenograft. While Mohammed et al. reported
a maximum tumour uptake of 6.7 % ID/g with [131I]IMBA in the murine melanoma model B16
[104], the tumour uptake values were signiﬁcantly lower for both 14b and 54 in the HHMSX
melanoma model. It is assumed that the diﬀerent tumour uptake values of [∗I]IMBA mainly
reﬂect diﬀerent physiological properties of the murine B16 and the human HHMSX melanoma
models. Consequently, a ﬁnal conclusion considering the melanoma-seeking properties of 54
could not be made.
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A standard reference melanoma model for biodistribution studies in mice is highly war-
ranted, facilitating comparison of tumour uptake values and comparison of the potential of
diﬀerent melanoma-seeking agents. Widespread use of the murine B16 melanoma model sug-
gests that this model should be used when investigating new melanoma-seeking agents, but
this melanoma model was not available for this work.
Tumour accumulation in the amelanotic melanoma model SESX
Amelanotic melanomas are characterised by melanocytes with no melanin synthesis. Hence,
it has been proposed that uptake of iodobenzamides goes via sigma-receptors expressed on
the melanoma cell membranes [109]. It has been shown that [131I]IMBA has moderate aﬃnity
for the σ1-receptor subgroup (K i = 249 ± 17 nM) [48], but the compound has not previously
been used for speciﬁc targeting of σ1-receptors in vivo. It is not known whether astatinated
benzamides have a similar aﬃnity for σ1-receptors as their iodinated analogues. On the other
hand, it is generally assumed that iodinated and astatinated analogues should have similar
in vivo behaviour, implying that 54 should have aﬃnity for σ1-receptor binding sites.
Pharmacology experiments showed a high density of σ1-receptors and a high-aﬃnity bind-
ing on the SESX cell membranes. Biodistributions studies in mice bearing the amelanotic
melanoma model SESX showed a small uptake in tumour for both 54 and 14b 1 h post-
injection (1.3 % ID/g and 1.0 % ID/g, respectively) [112]. However, only 14b showed high
melanoma/non-target tissue dose ratios, indicating tumour accumulation and tumour reten-
tion at the σ1-receptors (Table 7.2). Thus, the promising prospects of using 14b in speciﬁc
targeting of σ1-receptors were demonstrated (Paper III).
In contrast, the slow non-target tissue clearance of 54 hampered a corresponding evalu-
ation of the σ1-receptor aﬃnity of this benzamide (Table 7.2). The results did not show a
preferential accumulation of the astatinated analogue in amelanotic melanomas compared to
normal tissues, indicating that 54 can not be used as a radioligand in speciﬁc σ1-receptor
targeted radiotherapy (Paper III).
Comparison of the HHMSX and SESX studies
Figure 7.3 shows that the tumour uptake values of 14b and 54 in the pigmented HHMSX and
the non-pigmented SESX melanoma models were almost the same. This result indicates that
targeting of σ1-receptors may be of greater signiﬁcance in melanoma uptake of benzamides
than previously assumed.
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Figure 7.3: Tumour uptake values of [125I]IMBA 14b (left) and [211At]AMBA 54 (right) in
Balb/c nude mice bearing the melanoma xenografts HHMSX and SESX.
Conclusion
The astatinated benzamide 54 was considered stable to enzymatic deastatination in vivo,
but ineﬃcient as a melanoma-seeking agent for targeted radiotherapy of the melanotic and
amelanotic melanoma models HHMSX and SESX. The reported high contrast for scinti-
graphic imaging of malignant melanoma was conﬁrmed with 14b in both melanoma models.
The results indicated that 14b may be used for simple and eﬃcient targeting of cancerous
tissues expressing a high density of σ1-receptors. Consequently, targeting of σ1-receptors on
melanoma cell membranes may supplement the more complex uptake mechanism related to
melanin biosynthesis.
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Chapter 8
Malignant melanoma: Future
challenges
The main challenge in this ﬁeld is to develop an eﬃcient and speciﬁc melanoma-seeking agent.
In order to achieve this, it is imperative to identify the biologically active part(s) of chemical
structures responsible for melanoma uptake.
There is also a need for a better general understanding of the mechanisms by which
melanoma-seeking agents bind to melanotic tissue. The use of a standard reference model for
pigmented melanomas would enable proper comparison of the melanoma-seeking properties of
diﬀerent agents. Thus, characterisation and development of such a standard system is highly
required.
However, it is questionable whether the results obtained with melanoma-seeking agents in
a standard melanoma model will give results generally valid for clinical use, or whether the
results only will be representative for that speciﬁc melanoma model. For future investigations
it is important to ﬁnd the pigmented melanoma model which gives the most representative
results compared to the clinical situation in humans.
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Part III
BONE-RELATED CANCER
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Chapter 9
Bone-related cancer
Primary bone cancers are rare (less than 1% of all malignant tumours), although quite fre-
quent among children under age 15 [1, 34]. However, almost 50% of all soft tissue tumours
eventually spread to bone, making bone metastases a main problem in clinical oncology
[143, 144].
Generally, bone-related cancers are associated with skeletal pain, pathological fractures,
spinal cord compression, suppression of bone marrow function, hypercalcemia and ﬁnally
death. Besides palliative therapy to reduce pain, current treatment modalities includes
surgery, external beam irradiation, hormone therapy and chemotherapy. The therapeutic
eﬃciency is often limited due to severe side-eﬀects, and the number of patients with bone
metastases achieving complete curation is negligible. Alternative therapeutic methods for
tumour control and pain palliation are therefore highly required.
The development of new bone-seeking radiopharmaceuticals for targeted radiotherapy is
based on the well-known mechanisms of bone physiology and pathology.
9.1 Bone, osteosarcoma and bone metastasis
Bone tissue consists essentially of mineral (mainly hydroxyapatite Ca10(PO4)6(OH)2), organic
matrix, cells and water. The bone tissue is organised in an outer part consisting of tightly
packed bone tissue (cortical or compact bone) and an inner part consisting of porous bone
structures (trabecular or spongy bone) containing the red bone marrow [145, 146]. Bone
homeostasis is controlled by osteoblasts (bone-forming cells), osteoclasts (bone-resorbing cells)
and osteocytes (mature bone cells). Normally, there is an equilibrium between the osteoblasts
and osteoclasts maintaining the bone tissue. Generally, the remodulation of trabecular bone
is faster than that of cortical bone tissue [147].
Osteosarcoma is a primary malignant bone cancer originating from osseous tissue cells.
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It is usually of osteoblastic nature, forming a primitive tumoural bone matrix (osteoid).
Treatment is often problematic due to location (e.g. spine, skull, pelvis) and micrometastatic
spread to other organs, e.g. lungs.
Bone metastases are dominated by skeletal metastases arising from breast, prostate or
lung cancer [148]. Tumours metastasised to osseous tissue stimulate the osteoblastic and
osteoclastic activities, resulting in increased bone-turnover [147].
9.2 Bone-seeking radiopharmaceuticals
Bone-seeking radiopharmaceuticals with therapeutic properties are attractive alternatives to
external beam irradiation. The concept is based on the enhanced and selective uptake of bone-
seeking agents in tissues of high osteoblastic activity (e.g. in sclerotic lesions), combined with
radionuclides emitting short range radiation with high cytotoxicity. Hence, bone-seeking
radiopharmaceuticals may deliver high radiation doses to tumours with relative sparing of
healthy tissues, particularly the red bone marrow.
Therapeutic radiopharmaceuticals for bone pain palliation have been used successfully
for more than 30 years [149]. Nevertheless, only three bone-seeking radiopharmaceuticals
are currently approved by the FDA1 for routine clinical application in humans (Figure 9.1).
The 32P-sodium orthophosphate (59) was extensively used in the 1970s, but has been widely
replaced by 89SrCl2 (Metastron 60) and 153Sm-EDTMP (Quadramet 61). The latter
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Figure 9.1: Bone-seeking radiopharmaceuticals, of which agents 59–61 are approved by the
FDA.
1U.S. Food and Drug Administration.
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agents are equally eﬃcient, reporting signiﬁcant pain relief in 70–80% of patients, but less
radiotoxic to the red bone marrow than Na332PO4 [2, 149, 150].
Radiation-induced bone marrow suppression is the limiting factor when administrating
high radiation doses of bone-seeking radiopharmaceuticals, especially of agents emitting high-
energetic β−-particles (e.g. Na332PO4, 89SrCl2) [151, 152]. Consequently, new bone-seeking
agents have been labelled with radionuclides emitting medium- to low-energy β−-particles and
radionuclides decaying by electron capture (e.g. 153Sm-EDTMP 61, 186Re-HEDP 62, 117mSn-
DTPA 63, 177Lu-EDTMP 64) [17, 153–161]. Dense irradiation of bone tissues and sparing
of red bone marrow may also be achieved using α-emitting radionuclides (e.g. 223RaCl2 65)
[149, 162–165].
9.2.1 Bisphosphonates
Bisphosphonates is a group of bone-seeking agents extensively used in diagnosis and treat-
ment of diﬀerent bone-related diseases [166–168]. They have speciﬁc aﬃnity for bone matrix,
and accumulate in recently formed bone tissues in regions of high bone turnover [147]. Bis-
phosphonates are also characterised by a high in vivo stability, favourable kinetics and low
toxicity.
All bisphosphonates contain a metabolically stable P–C–P structure 66 (Figure 9.2). The
phosphonate groups and the R1 side chain are essential for the chemisorption to hydroxy-
apatite, while R2 determines the pharmacological properties of the compound. Thus, R2 is
the key for making radiolabelled bisphosphonates for radiotherapeutic applications as this
side chain does not interfer with the bone-seeking properties [147].
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Figure 9.2: Examples of bisphosphonates investigated as bone-seeking agents. The structure
of the 99mTc-MDP complex 68 is indicated (from Refs. [169, 170]).
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Eisenhut et al. were ﬁrst to evaluate the potential of 131I-labelled bisphosphonates for
treatment of bone metastases [171–174]. Several benzylidenebisphosphonates 67 were syn-
thesised (Figure 9.2), showing bone aﬃnity and selectivity comparable to other bone-seeking
agents, e.g. 99mTc-methylene diphosphonate (99mTc-MDP 68). However, the in vivo stability
was low, with considerable deiodination and subsequent uptake of 131I-iodide in the thyroid.
A slightly higher bone aﬃnity and selectivity was found with radiohalogenated aromatic ami-
dobisphosphonates 69 [175, 176].
Recently, A˚rstad et al. synthesised and characterised a series of new 131I-labelled arylalkyl-
idenebisphosphonates, of which 1-hydroxy-(m-[131I]iodophenyl)ethylidene-1,1-bisphosphonic
acid ([131I]HIPEBA 70c, Figure 9.2) showed high in vivo stability, negligible uptake in thyroid
and a bone aﬃnity superior to both 89SrCl2 60 and 153Sm-EDTMP 61 [177, 178]. Thus, it is
assumed that [131I]HIPEBA 70c may ﬁnd use in diagnosis as well as in curative and palliative
treatment of bone-related cancers [178].
9.3 Aim of study
The objective of this study was to evaluate the prospective use of the radioiodinated bisphos-
phonate [∗I]HIPEBA 70 in targeted radiotherapy of bone-related cancer in humans. The
speciﬁc aim was to characterise the initial pharmacokinetics of [123I]HIPEBA 70b in an
animal model resembling humans with respect to skeletal growth patterns as well as liver and
kidney functions.
Chapter 10
Methods
10.1 Radioactivity measurements
Radioactivity measurements of radioiodine and preparations of [∗I]HIPEBA 70 were carried
out with a VDC-304 dose calibrator (Veenstra Instrumenten bv). Scintigraphic imaging of
[123I]HIPEBA 70b in pigs was performed using a mobile Picker CX 250 compact gamma-
camera equipped with a general purpose collimator (Paper V).
10.2 Chromatography
The radio-HPLC system for puriﬁcation and isolation of [∗I]HIPEBA 70 was developed by
A˚rstad [177]. The system was based on a PLRP-S 100 A˚ styrene-divinylbenzene column
(stationary phase) and a polar mobile phase run under isocratic conditions. A proper sample
preparation prior to radio-HPLC was critical to avoid clogging of the column. The best results
were obtained when the reaction mixture was added aqueous phosphoric acid and mixed in
an ultrasound bath for ∼10min before injection on the column [177]. Detailed speciﬁcations
of the radio-HPLC system, instruments and detectors are found in Paper V.
10.3 Animals
Healthy young pigs (3 months) of both genders were transported to the large animal facility
at the Center for Comparative Medicine, University of Oslo, one day prior to the experi-
ment (Paper V). Housing and all procedures involving animals were performed according to
protocols approved by the animal care and use committee, in compliance with the National
Committee for Animal Experiment’s guidelines on animal welfare [113, 114]. The animals
were anaesthetised as described in Paper V.
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10.4 The FNOMIP method
The new scintigraphic image analysis method FNOMIP (”ﬁxed number of most intense
pixels”) was developed by Skretting in connection with the experiment described in Paper
V [179, 180]. The FNOMIP method ensures that a selective region of interest (SROI) has
a constant size and covers the same anatomical structure at all time points during a study,
thus correcting for small movements and for diﬀerent animal positions in static studies. The
method is illustrated in Figure 10.1. This method enables generation of dynamic uptake
curves using the total number of counts in a SROI covering a speciﬁc anatomical structure
(Paper V).
Figure 10.1: Illustration of the FNOMIP method. Upper frame shows the original images,
while the lower frame shows the automatically generated selective regions of interest (black
regions) of the knee of a pig administrated [123I]HIPEBA 70b. Note the movement of the
knee between image 6–8.
10.5 The OLINDA/EXM code
The OLINDA/EXM personal computer code performs dose calculations and kinetic modeling
of radiopharmaceuticals [181]. The estimated radiation dose to diﬀerent organs of the human
body can be calculated from user-supplied biokinetic data obtained from animal or human
studies (Paper V).
Chapter 11
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11.1 Introduction
Previous biodistribution studies with [∗I]HIPEBA 70 in healthy and tumour-bearing rodents
have demonstrated a potential for this radioiodinated bisphosphonate as a bone-seeking agent
in diagnosis and targeted radiotherapy of bone-related cancer [177, 178]. To provide a basis
for future clinical trials in humans, [∗I]HIPEBA 70 should be investigated in an animal model
more closely resembling humans with respect to skeletal growth patterns, liver and kidney
functions.
In this study, the 123I-labelled HIPEBA was synthesised and its initial pharmacokinetic
properties investigated in young pigs using gamma-camera imaging.
11.2 Chemistry
The silylated bisphosphonate 1-hydroxy-(m-trimethylsilylphenyl)ethylidene-1,1-bisphos-
phonic acid (71) was provided by A˚rstad, and was radiolabelled and isolated according to
literature procedures (Figure 11.1) [177].
Precursor 71 was radioiodinated under acidic conditions using NCS as an oxidis-
SiMe3
HO PO3H2
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HO PO3H2
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71 70b
Figure 11.1: Radioiodination of the silylated precursor 71 yielding [123I]HIPEBA 70b.
Reagents and conditions: a) Na123I, NCS, AcOH, TFA, rt; b) H3PO4(aq), ultrasound, rt.
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ing agent, yielding the radioiodinated product 1-hydroxy-(m-[123I]iodophenyl)ethylidene-1,1-
bisphosphonic acid ([123I]HIPEBA 70b). Puriﬁcation by radio-HPLC yielded the radio-
iodinated bisphosphonate 70b in >95% integrated radiochemical yield. However, the
yield of isolated material was only 35–40%. The ﬁnal preparation consisted of 1.3GBq
[123I]HIPEBA 70b in 15.7mL of sterile ﬁltered phosphate buﬀer (50mM, pH 7.1, added
2% EtOH). The radioiodination is depicted in Figure 11.1, and detailed descriptions of the
procedure are found in Paper V.
11.3 Biology
The following experiment in pigs was approved by the Committee of Ethics for the use of
Animals in Research in Norway.
Biodistribution studies were conducted at the Center for Comparative Medicine, Univer-
sity of Oslo, using four 3 months old pigs (two of each gender) weighing 17–21 kg (Paper V).
The animals were anaesthetised using Stresnil vet/Ketalar/Pentotal, then two of the pigs (one
of each gender) were administered [123I]HIPEBA 70b (204MBq and 234MBq, respectively)
while the other two pigs were administered the reference compound 99mTc-MDP 68 (126MBq
and 107MBq, respectively). The pigs were sacriﬁed after 8 h by injection of Pentotal.
11.4 Imaging and analysis
Biodistribution and biodynamics of [123I]HIPEBA 70b (t1/2 13.2 h, 159 keV γ in 83.3%) and
99mTc-MDP 68 (t1/2 6.02 h, 141 keV γ in 87.2%) were investigated using a mobile gamma-
camera. Dynamic imaging studies were carried out during the ﬁrst 30min post-injection,
followed by static imaging studies for 5min at speciﬁc time intervals up to 7.5 h (Paper V).
The analysis of bone deposition patterns was based on a visual comparison of static
images obtained with 70b and 68. Dynamic curves for uptake in knee were obtained using
the FNOMIP method [179, 180].
11.5 Radiation dose estimates in humans
Estimated absorbed radiation doses for administration of the 131I-labelled HIPEBA 70c (t1/2
192.48 h, mean β−-energy 0.182MeV) and 153Sm-EDTMP 61 (t1/2 46.27 h, mean β−-energy
0.225MeV) in humans were obtained using the OLINDA/EXM code (adult male model) [181].
The input values for the surfaces of trabecular and cortical bone in humans were obtained
from data on ”Reference man” [182], and the calculations were made under the assumption
that accumulated 70c was not released from bone surfaces. It was assumed that 100% of 70c
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Figure 11.2: Static images showing the uptake of [123I]HIPEBA 70b (left) and 99mTc-MDP 68
(right) in head and neck, thorax and pelvis of the pigs 4 h post-injection.
and 80% of 61 were adsorbed on bone surfaces. To facilitate a direct comparison between
70c and 61, the estimated dose values of 61 were converted to correct for the diﬀerence in
half-lives (Paper V).
11.6 Results and discussion
Biodistribution studies were conducted in healthy young pigs to compare the initial pharmaco-
kinetic properties of [123I]HIPEBA 70b with those of the standard bone scintigraphic agent
99mTc-MDP 68 (Paper V). The results are summarised in Figure 11.2.
Visual inspection of static gamma-camera images of the neck 4 h post-injection showed
no accumulation of 70b in the thyroid (Figure 11.2). This result veriﬁed the in vivo stability
reported for this radioiodinated bisphosphonate in previous studies [177, 178]. However,
thyroid blocking agents may be used as a precaution in clinical studies with [∗I]HIPEBA 70
in humans.
Dynamic studies of the knee revealed that the bone uptake patterns of 70b and 68 were
indistinguishable during the ﬁrst 0.5 h post-injection. However, 70b showed a higher bone
accumulation than 68 at later time points, and the uptake increased throughout the experi-
ment. The lower bone accumulation of 68 was due to a rapid renal excretion (Figure 11.2)
which reduced the amount of 68 available for uptake in bone. In contrast, a negligible renal
excretion of 70b indicated that almost all the injected activity would end up in bone tissue.
These observations were also consistent with the diﬀerent biological half-lives calculated for
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Table 11.1: Estimated absorbed radiation doses for injection of [131I]HIPEBA 70c and 153Sm-
EDTMP 61 in humans. The values were obtained using the OLINDA/EXM code (adult male
model). The dose values for 61 have been converteda to enable direct comparison with 70c.
[131I]HIPEBA 153Sm-EDTMPconverted
Organ Dose (mSv/MBq) Dose (mSv/MBq)a
Red bone marrow 4.51 4.66
Osteogenic cells 16.7 24.34
Ovaries 0.24 0.025
Testes 0.13 0.012
Thyroid 0.24 0.029
Eﬀective whole body dose 0.86 0.82
a Converted 153Sm-EDTMP dose = Estimated 153Sm-EDTMP dose * T1/2(
131I) / T1/2(
153Sm)
the blood/extravascular compartments (Paper V).
The results indicated that [∗I]HIPEBA 70 may have favourable properties as a bone-
seeking agent in targeted radiotherapy of osseous bone metastases and osteosarcomas in
humans. Thus, the radiotherapeutic prospects of the 131I-labelled HIPEBA 70c were
estimated and compared to the bone-seeking radiopharmaceutical 153Sm-EDTMP 61 using
the OLINDA/EXM code. The estimated radiation doses for 70c and 61 were very similar for
red bone marrow, osteogenic cells and for the eﬀective whole body dose (Table 11.1). How-
ever, the estimated doses to more distant critical organs were larger for 70c due to emission
of photons with higher energies and yields.
Conclusion
The results obtained with [123I]HIPEBA 70b in pigs indicated high in vivo stability and
a bone uptake comparable to 99mTc-MDP 68. Estimated radiotherapeutic properties of
[131I]HIPEBA 70c were comparable to the FDA-approved 153Sm-EDTMP 61. Negligible
renal uptake and excretion of [∗I]HIPEBA 70 facilitate diagnostic scintigraphic imaging of
the pelvis and is particularly advantageous for targeted radiotherapy, minimising the radia-
tion doses to kidneys and bladder walls. Hence, future investigations of the biodynamics of
[∗I]HIPEBA 70 in humans are justiﬁed.
Chapter 12
Bone-related cancer: Future
prospects
High accumulation of HIPEBA in bone combined with an almost negligible renal excretion
indicate that [123I]HIPEBA and [124I]HIPEBA may be used in diagnosis of bone-forming
malignancies in SPECT and PET, respectively. The compounds are particularly advantageous
for investigations of the pelvis, and may thus be used as a supplement to current bone-seeking
agents with considerable renal excretion (e.g. 99mTc-MDP, 153Sm-EDTMP).
The HIPEBA may also have a future in palliative and curative treatment of bone meta-
stases using therapeutic radionuclides like 131I and 211At. The [131I]HIPEBA has a much more
favourable half-life than 89SrCl2 and 153Sm-EDTMP, and is more easily available at low cost
provided that a kit for in situ 131I-labelling is developed. A more strongly focused dose to
micrometastases containing bone tissue may be obtained using the 211At-labelled analogue of
HIPEBA. The rapid distribution and bone accumulation of HIPEBA are advantageous with
regard to the relatively short half-life of 211At. Thus, the 211At-labelled analogue may have
potential in treatment of osseous micrometastases, while [131I]HIPEBA would be more eﬃ-
cient for metastatic lesions where pathologically enhanced bone formation is inhomogenously
distributed. Treatment of bone-related cancers may also beneﬁt from using [131I]HIPEBA in
combination with other bone-seeking radiopharmaceuticals emitting high-LET radiation, e.g.
223RaCl2. The radiation dose to red bone marrow will be the limiting factor in humans, unless
stem cell support is oﬀered.
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Appendix A
Chemical abbreviations
Table A.1: Chemical abbreviations
Azure B 3-dimethylamino-7-methylaminophenothiazin-5-ylium chloride
(BOC)2O di-tert-butyl dicarbonate
Bu3SnAr-OTFP 4-(tri-n-butylstannyl)benzoic acid-2,3,5,6-tetraﬂuorophenyl ester
Bu3SnCl tri-n-butyltin chloride
n-BuLi n-butyllitium
Bu6Sn2 hexa-n-butyldistannane
(CH3)3COK potassium tert-butoxide
DCC N,N’ -dicyclohexylcarbodiimide
4-DMAP 4-dimethylaminopyridine
DMF N,N -dimethylformamide
DMSO dimethylsulphoxide
DTPA diethylenetriamine pentaacetic acid
EDC N -(3-dimethylaminopropyl)-N’ -ethylcarbodiimide hydrochloride
EDTMP ethylene diamine tetramethylene phosphonate
HEDP hydroxyethylidene diphosphonate
IAr-OTFP 4-iodobenzoic acid-2,3,5,6-tetraﬂuorophenyl ester
NCS N -chlorosuccinimide
NHS N -hydroxysuccinimide
PBS phosphate buﬀered saline
Ph3P triphenylphosphine
[Ph3P]4Pd tetrakis(triphenylphosphine)palladium(0)
TFA triﬂuoroacetic acid
TFP-OH 2,3,5,6-tetraﬂuorophenol
THF tetrahydrofuran
Tl(TFA)3 thallium (III) triﬂuoroacetate
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Appendix B
Glossary of radiochemical and
medical terms
Table B.1: Glossary of radiochemical and medical terms
α-particle a helium nucleus; 4He2+
ad libitum in accordance with desire
amelanotic non-pigmented; do not produce melanin
amelanotic melanoma a form of melanoma in which the malignant cells (melanocytes)
do not synthesise the pigment melanin
β−-particle an electron; e−
β+-particle a positron; e+
epidermis the outermost layer of the skin
in situ in position; in the natural or original position or place
in vivo in the living; in the living body of a plant or animal
in vitro in glass; outside the living body and in an artiﬁcial environment
LET linear energy transfer; a measure of energy deposition from a charged
particle to a medium per unit length
melanin pigments present in animal or plant structures (as skin or hair);
black, dark brown, reddish-brown or yellow
melanocyte an epidermal cell which produces melanin
melanoma a highly malignant tumour arising from melanocytes in normal
skin or moles
melanosome melanin-producing organelle found in the melanocytes
melanotic pigmented; melanin-producing
melanogenesis the formation of melanin; melanin synthesis
PET positron emission tomography
RBE relative biological eﬀectiveness
SPECT single photon emission computed tomography
xenografts cells, tissues or organs which are transplanted from one species to another
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Appendix C
Additional spectroscopic data
1H- and 13C-NMR spectra were recorded on a Bruker DPX 300 MHz instrument, and the chemical shifts were calibrated
using the CHCl3-signal. Electron ionisation mass spectrometry was performed on a Micromass Prospec Q instrument.
Aromatic activated tetraﬂuorophenyl esters
4-iodobenzoic acid-2,3,5,6-tetraﬂuorophenyl ester (18): 1H-NMR (CDCl3): δ 7.03 (m, 1 H, PhH4); 7.90 (s, 4
H, PhH2′ ,3′,5′,6′ ).
13C-NMR: δ 103.0 103.4 126.6 131.9 138.3 162.2. MS (EI): m/z 396 (M+ not detected), 231
(100), 203 (20) and 104 (9).
4-tributylstannylbenzoic acid-2,3,5,6-tetraﬂuorophenyl ester (16): 1H-NMR (CDCl3): δ 0.8–1.6 (m, 27 H,
-Sn(C4H9)3); 7.01 (m, 1 H, PhH4); 7.62 (d, 2 H, J = 9 Hz, PhH3′,5′ ); 8.08 (d, 2 H, J = 9 Hz, PhH2′ ,6′ ).
13C-NMR: δ 9.8 13.8 27.4 29.1 129.4 136.8. MS (EI): m/z 559 (M+ not detected), 503 (100), 447 (32), 391 (54),
196 (8), 161 (8), and 105 (18).
Brominated cysteaminylphenol derivatives
2-bromo-4-thiocyanatophenol (43): 1H-NMR (CDCl3): δ 5.8 (broad, 1 H, Ar-OH); 7.06 (d, 1 H, J = 9 Hz, PhH6);
7.43 (dd, 1 H, J = 2 and 9 Hz, PhH5); 7.71 (d, 1 H, J = 2 Hz, PhH3). 13C-NMR: δ 111.5 117.8 128.4 133.2
135.5 152.7. MS (EI): m/z 231 (M+ 92), 229 (92), 150 (100), 122 (67) and 95 (19).
2,2’-dibromo-4,4’-dimercaptodiphenol (38): 1H-NMR (CDCl3): 1H-NMR (CDCl3): δ 5.6 (broad, 2 H, Ar-OH);
6.93 (d, 2 H, J = 9 Hz, PhH6); 7.28 (dd, 2 H, J = 2 and 9 Hz, PhH5); 7.56 (d, 2 H, J = 2 Hz, PhH3).
13C-NMR: δ 110.6 116.8 129.5 132.2 134.4 152.9. MS (EI): m/z 410 (M+ 57), 408 (100), 406 (50), 205 (99), 204
(62), 203 (92), 125 (21), 124 (31) and 95 (31).
N -[2-(4-hydroxy-3-bromo-phenylsulphanyl)ethyl]acetamide (35): 1H-NMR (CDCl3): δ 1.96 (s, 3 H,
-NH(CO)CH3); 2.94 (t, 2 H, J = 7 Hz, -SCH2CH2NH-); 3.40 (q, 2 H, J = 6 Hz, -SCH2CH2NH-); 5.80 (broad,
1 H, Ar-OH); 6.94 (d, 1 H, J = 9 Hz, PhH5); 7.27 (dd, 1 H, J = 2 and 9 Hz, PhH6); 7.54 (d, 1 H, J = 2 Hz,
PhH2). 13C-NMR: δ 23.2 35.5 38.6 111.0 116.8 127.5 133.0 135.3 152.3 170.4. MS (EI): m/z 291 (M+ 9), 289
(8), 232 (100), 230 (98), 151 (77), 138 (14) and 86 (76).
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Appendix D
Biodistribution data
Table D.1: Biodistribution data of 28b and 32b in normal Balb/c nude mice.
Organ 0.5 ha 2 h 6 h
28b
Blood 2.0 ± 0.2 0.7 ± 0.4 0.38 ± 0.07
Eye 0.39 ± 0.03 -0.2 ± 0.8 0.04 ± 0.25
Muscle 0.6 ± 0.2 0.21 ± 0.08 0.2 ± 0.2
Lung 1.5 ± 0.2 1.3 ± 0.6 0.31 ± 0.06
Kidney 4.7 ± 0.9 0.6 ± 0.1 0.7 ± 0.7
Spleen 0.6 ± 0.1 0.4 ± 0.2 0.22 ± 0.05
Liver 8.6 ± 0.9 1.9 ± 1.0 0.32 ± 0.09
Stomachb 1.3 ± 0.9 4.9 ± 2.9 1.7 ± 0.3
Intestineb 4.7 ± 3.6 14.7 ± 0.4 4.7 ± 1.7
Urine 96.5 ± 56.6 43.2 ± 20.1 79.1 ± 23.1
Thyroid 1.2 ± 0.3 3.7 ± 2.0 3.3 ± 3.0
32b
Blood 2.6 ± 0.1 1.3 ± 0.4 0.4 ± 0.2
Eye 0.57 ± 0.05 0.5 ± 0.2 0.18 ± 0.04
Muscle 0.6 ± 0.2 0.31 ± 0.07 0.1 ± 0.1
Lung 1.8 ± 0.2 1.4 ± 0.4 0.3 ± 0.1
Kidney 6.5 ± 0.5 1.09 ± 0.06 0.4 ± 0.3
Spleen 1.2 ± 0.3 0.8 ± 0.2 0.2 ± 0.1
Liver 4.3 ± 0.4 1.4 ± 0.7 0.16 ± 0.05
Stomachb 2.8 ± 1.3 6.5 ± 2.9 2.0 ± 0.8
Intestineb 3.8 ± 2.3 7.8 ± 1.4 0.5 ± 0.1
Urine 124.1 ± 79.1 80.7 ± 27.9 42.8 ± 14.3
Thyroid 3.4 ± 0.9 7.9 ± 3.2 4.9 ± 4.7
a Values are mean % ID/g ± SD (n = 4).
b Gastric and intestinal values include their contents.
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Table D.2: Biodistribution data of 30b and 33c in normal Balb/c nude mice.
Organ 0.5 ha 2 h 6 h
30b
Blood 1.8 ± 1.2 0.7 ± 0.2 0.2 ± 0.1
Eye 0.49 ± 0.08 -0.04 ± 0.54 -0.04 ± 0.19
Muscle 0.6 ± 0.1 0.22 ± 0.05 0.04 ± 0.02
Lung 4.8 ± 2.3 0.9 ± 0.4 0.27 ± 0.09
Kidney 3.4 ± 1.3 1.2 ± 0.3 0.9 ± 0.5
Spleen 0.8 ± 0.6 0.22 ± 0.05 0.07 ± 0.02
Liver 5.6 ± 1.3 7.0 ± 2.5 3.4 ± 0.6
Stomachb 8.5 ± 9.8 5.9 ± 3.6 0.5 ± 0.2
Intestineb 3.2 ± 0.9 6.0 ± 8.8 11.5 ± 4.7
Urine 168.2 ± 137.3 22.1 ± 26.9 49.6 ± 8.7
Thyroid 2.2 ± 0.3 1.1 ± 0.3 0.5 ± 0.4
33c
Blood 3.4 ± 0.9 0.9 ± 0.2 0.3 ± 0.1
Eye 1.0 ± 0.2 0.5 ± 0.2 0.10 ± 0.03
Muscle 1.0 ± 0.1 0.26 ± 0.05 0.05 ± 0.01
Lung 4.1 ± 1.5 1.1 ± 0.2 0.3 ± 0.1
Kidney 6.5 ± 2.3 1.6 ± 0.4 0.8 ± 0.5
Spleen 1.3 ± 0.5 0.52 ± 0.04 0.14 ± 0.05
Liver 4.9 ± 1.3 3.4 ± 1.6 1.0 ± 0.2
Stomachb 7.4 ± 6.0 8.3 ± 2.2 1.6 ± 0.5
Intestineb 3.2 ± 0.7 5.7 ± 7.6 7.4 ± 2.8
Urine 352.9 ± 316.6 24.9 ± 29.8 41.2 ± 7.4
Thyroid 4.5 ± 0.5 5.9 ± 2.3 2.5 ± 2.1
a Values are mean % ID/g ± SD (n = 4).
b Gastric and intestinal values include their contents.
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Table D.3: Biodistribution of 28b and 29 in Balb/c nude mice bearing the melanotic
melanoma xenograft HHMSX.
Organ 0.5 ha 2 h 6 h 16 h
28b
Blood 0.103 ± 0.009 0.09 ± 0.03 0.016 ± 0.005 0.003 ± 0.001
Tumour 0.06 ± 0.03 0.06 ± 0.02 0.014 ± 0.006 0.004 ± 0.003
Muscle 0.04 ± 0.05 0.024 ± 0.008 0.007 ± 0.001 0.002 ± 0.003
Lung 0.16 ± 0.02 0.11 ± 0.03 0.017 ± 0.003 0.006 ± 0.002
Kidney 0.6 ± 0.2 0.2 ± 0.1 0.04 ± 0.01 0.009 ± 0.007
Spleen 0.07 ± 0.03 0.07 ± 0.03 0.009 ± 0.003 0.005 ± 0.003
Liver 0.7 ± 0.4 0.3 ± 0.2 0.029 ± 0.008 0.007 ± 0.002
Large intestineb 0.10 ± 0.02 1.2 ± 0.5 0.10 ± 0.07 0.009 ± 0.003
Urine 62.6 ± 41.9 15.2 ± 7.5 8.5 ± 5.0 0.6 ± 0.4
Thyroid 0.17 ± 0.03 0.3 ± 0.2 0.08 ± 0.04 0.004 ± 0.002
Stomachb 1.5 ± 0.7 1.2 ± 0.5 0.16 ± 0.08 0.015 ± 0.003
Skin 0.08 ± 0.01 0.10 ± 0.02 0.046 ± 0.007 0.010 ± 0.003
Tail 0.30 ± 0.06 0.17 ± 0.07 0.17 ± 0.05 0.05 ± 0.05
Eye 0.027 ± 0.009 0.04 ± 0.01 0.013 ± 0.004 0.011 ± 0.005
Heart 0.05 ± 0.02 0.05 ± 0.02 0.011 ± 0.002 0.002 ± 0.002
Femur 0.04 ± 0.02 0.04 ± 0.01 0.010 ± 0.009 0.000 ± 0.004
Brain 0.007 ± 0.001 0.005 ± 0.002 0.003 ± 0.002 0.001 ± 0.001
Small intestineb 4.4 ± 3.3 1.5 ± 1.2 0.2 ± 0.1 0.012 ± 0.003
29
Blood 1.39 ± 0.08 1.2 ± 0.2 0.6 ± 0.2 0.4 ± 0.1
Tumour 1.7 ± 0.4 2.3 ± 0.4 1.5 ± 0.4 0.7 ± 0.2
Muscle 0.59 ± 0.05 0.7 ± 0.1 0.37 ± 0.08 0.15 ± 0.05
Lung 9.5 ± 1.3 8.9 ± 1.7 5.0 ± 1.5 2.5 ± 0.8
Kidney 4.4 ± 0.2 4.1 ± 0.2 2.1 ± 0.5 1.0 ± 0.4
Spleen 7.5 ± 0.4 8.1 ± 2.1 3.7 ± 0.5 2.2 ± 0.6
Liver 1.5 ± 0.1 1.5 ± 0.3 0.8 ± 0.2 0.4 ± 0.1
Large intestineb 1.8 ± 0.4 2.5 ± 0.6 0.9 ± 0.2 0.5 ± 0.1
Urine 32.7 ± 25.0 7.8 ± 2.7 24.8 ± 5.9 5.2 ± 0.9
Thyroid 6.0 ± 0.4 8.9 ± 2.5 6.6 ± 1.6 2.0 ± 0.6
Stomachb 14.8 ± 7.4 14.9 ± 5.2 12.7 ± 3.4 5.6 ± 1.3
Skin 2.7 ± 0.2 2.8 ± 0.2 1.8 ± 0.8 1.2 ± 0.3
Tail 2.3 ± 0.1 2.0 ± 0.1 1.5 ± 0.5 0.7 ± 0.2
Eye 0.89 ± 0.05 0.9 ± 0.2 0.5 ± 0.2 0.2 ± 0.2
Heart 2.9 ± 0.4 2.9 ± 0.4 1.5 ± 0.4 0.7 ± 0.2
Femur 1.4 ± 0.1 1.4 ± 0.3 0.7 ± 0.2 0.5 ± 0.2
Brain 0.27 ± 0.04 0.22 ± 0.02 0.14 ± 0.07 0.04 ± 0.04
Small intestineb 2.7 ± 0.4 2.5 ± 0.6 1.1 ± 0.3 0.6 ± 0.2
a Values are mean % ID/g ± SD (n = 4).
b Gastric and intestinal values include their contents.
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Table D.4: Biodistribution of 30b and 31 in Balb/c nude mice bearing the melanotic
melanoma xenograft HHMSX.
Organ 0.5 ha 2 h 6 h 16 h
30b
Blood 0.26 ± 0.03 0.08 ± 0.01 0.023 ± 0.006 0.004 ± 0.001
Tumour 0.17 ± 0.02 0.069 ± 0.008 0.023 ± 0.007 0.010 ± 0.004
Muscle 0.071 ± 0.005 0.025 ± 0.008 0.006 ± 0.003 0.002 ± 0.002
Lung 0.21 ± 0.02 0.06 ± 0.01 0.020 ± 0.001 0.007 ± 0.002
Kidney 0.9 ± 0.2 0.29 ± 0.08 0.12 ± 0.03 0.017 ± 0.003
Spleen 0.088 ± 0.003 0.046 ± 0.009 0.02 ± 0.01 0.005 ± 0.002
Liver 1.4 ± 0.2 1.1 ± 0.3 0.4 ± 0.2 0.043 ± 0.009
Large intestineb 0.22 ± 0.08 2.6 ± 1.5 0.6 ± 0.2 0.06 ± 0.03
Urine 55.5 ± 28.0 51.7 ± 18.2 14.1 ± 2.8 0.38 ± 0.09
Thyroid 0.20 ± 0.03 0.11 ± 0.03 0.03 ± 0.01 0.004 ± 0.002
Stomachb 0.6 ± 0.3 0.7 ± 0.4 0.2 ± 0.2 0.01 ± 0.01
Skin 0.23 ± 0.04 0.06 ± 0.01 0.028 ± 0.005 0.02 ± 0.01
Tail 1.1 ± 0.7 0.3 ± 0.2 0.16 ± 0.09 0.11 ± 0.08
Eye 0.05 ± 0.02 0.017 ± 0.007 0.000 ± 0.008 -0.003 ± 0.003
Heart 0.17 ± 0.02 0.045 ± 0.004 0.016 ± 0.006 0.003 ± 0.002
Femur 0.06 ± 0.01 0.024 ± 0.006 0.004 ± 0.008 0.001 ± 0.004
Brain 0.031 ± 0.006 0.009 ± 0.005 0.003 ± 0.001 0.001 ± 0.001
Small intestineb 7.4 ± 0.8 2.3 ± 0.8 1.1 ± 0.4 0.03 ± 0.02
31
Blood 1.0 ± 0.2 0.8 ± 0.1 0.6 ± 0.2 0.49 ± 0.06
Tumour 0.7 ± 0.4 2.4 ± 0.7 1.7 ± 1.0 -0.5 ± 2.6
Muscle 0.3 ± 0.4 0.4 ± 0.2 0.3 ± 1.0 NDc
Lung 10.2 ± 4.7 10.1 ± 4.0 8.8 ± 5.8 5.6 ± 3.7
Kidney 2.7 ± 0.9 3.8 ± 1.4 3.8 ± 0.7 1.7 ± 0.6
Spleen 4.8 ± 2.2 10.3 ± 5.3 7.3 ± 2.2 5.6 ± 3.6
Liver 1.7 ± 0.5 1.1 ± 0.2 1.3 ± 0.4 0.8 ± 0.4
Large intestineb 1.0 ± 0.3 2.7 ± 0.9 1.9 ± 0.7 1.1 ± 0.3
Urine 47.1 ± 23.7 39.3 ± 33.9 55.8 ± 21.3 13.0 ± 2.9
Thyroid 3.3 ± 0.8 6.3 ± 1.2 12.5 ± 6.6 5.6 ± 3.8
Stomachb 8.9 ± 2.2 26.7 ± 14.4 18.4 ± 4.6 9.8 ± 6.3
Skin 1.6 ± 0.6 2.2 ± 1.1 2.9 ± 1.1 2.5 ± 0.7
Tail 2.8 ± 0.8 1.9 ± 0.9 1.6 ± 0.3 0.8 ± 0.2
Eye -0.2 ± 0.6 -0.2 ± 0.8 -0.2 ± 1.2 ND
Heart 1.6 ± 0.3 3.1 ± 1.2 2.6 ± 1.1 ND
Femur 0.9 ± 0.6 1.7 ± 0.6 1.3 ± 1.9 ND
Brain 0.2 ± 0.2 0.2 ± 0.1 0.2 ± 0.4 ND
Small intestineb 5.5 ± 0.6 1.8 ± 0.4 1.2 ± 0.4 0.9 ± 0.3
a Values are mean % ID/g ± SD (n = 4).
b Gastric and intestinal values include their contents.
c ND = not detected.
92 Biodistribution data
Table D.5: Biodistribution of 32b in Balb/c nude mice bearing the melanotic melanoma
xenograft HHMSX.
Organ 0.5 ha 2 h 6 h 16 h
32b
Blood 0.04 ± 0.02 0.04 ± 0.02 0.003 ± 0.001 0.002 ± 0.008
Tumour 0.05 ± 0.02 0.04 ± 0.02 0.005 ± 0.004 0.007 ± 0.001
Muscle 0.02 ± 0.02 0.009 ± 0.004 -0.001 ± 0.009 -0.004 ± 0.017
Lung 0.03 ± 0.01 0.05 ± 0.02 -0.002 ± 0.004 -0.001 ± 0.012
Kidney 0.14 ± 0.04 0.11 ± 0.05 -0.001 ± 0.007 -0.004 ± 0.008
Spleen 0.03 ± 0.03 0.03 ± 0.02 0.003 ± 0.007 0.000 ± 0.003
Liver 0.15 ± 0.06 0.12 ± 0.05 0.001 ± 0.001 0.001 ± 0.003
Large intestineb 0.08 ± 0.06 0.10 ± 0.06 0.01 ± 0.02 -0.008 ± 0.011
Urine 70.9 ± 14.2 6.7 ± 4.2 0.3 ± 0.3 0.7 ± 0.8
Thyroid 0.06 ± 0.03 0.13 ± 0.09 0.005 ± 0.016 0.06 ± 0.06
Stomachb 0.5 ± 0.4 0.3 ± 0.2 0.02 ± 0.01 0.03 ± 0.03
Skin 0.04 ± 0.02 0.03 ± 0.02 0.009 ± 0.005 0.006 ± 0.008
Tail 0.10 ± 0.03 0.07 ± 0.03 0.008 ± 0.007 0.021 ± 0.008
Eye 0.02 ± 0.05 -0.005 ± 0.036 -0.003 ± 0.045 0.005 ± 0.037
Heart 0.02 ± 0.02 0.02 ± 0.02 0.002 ± 0.010 0.005 ± 0.010
Femur -0.004 ± 0.026 0.03 ± 0.02 0.006 ± 0.006 0.01 ± 0.03
Brain 0.002 ± 0.004 0.005 ± 0.007 0.000 ± 0.003 0.001 ± 0.002
Small intestineb 0.6 ± 0.5 0.2 ± 0.1 0.006 ± 0.007 0.001 ± 0.006
a Values are mean % ID/g ± SD (n = 4).
b Gastric and intestinal values include their contents.
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Table D.6: Biodistribution of 33b and 53 in Balb/c nude mice bearing the melanotic
melanoma xenograft HHMSX.
Organ 0.5 ha 2 h 6 h 16 h
33b
Blood 0.8 ± 0.1 0.4 ± 0.1 0.04 ± 0.01 0.07 ± 0.04
Tumour 0.7 ± 0.4 0.24 ± 0.07 0.03 ± 0.01 0.05 ± 0.03
Muscle 0.23 ± 0.07 0.08 ± 0.02 0.013 ± 0.006 0.03 ± 0.05
Lung 0.7 ± 0.1 0.7 ± 0.4 0.08 ± 0.02 0.11 ± 0.02
Kidney 2.9 ± 1.3 1.5 ± 0.7 0.14 ± 0.02 0.3 ± 0.1
Spleen 0.6 ± 0.3 0.3 ± 0.1 0.02 ± 0.01 0.05 ± 0.03
Liver 3.5 ± 1.1 2.0 ± 0.6 0.16 ± 0.04 0.31 ± 0.06
Large intestineb 3.1 ± 2.6 11.2 ± 3.5 1.6 ± 0.9 3.2 ± 1.4
Urine 312.9 ± 51.1 33.6 ± 15.3 8.0 ± 1.1 11.5 ± 3.3
Thyroid 1.3 ± 0.3 1.2 ± 0.2 0.2 ± 0.1 0.6 ± 0.6
Stomachb 9.0 ± 5.6 4.4 ± 2.2 0.2 ± 0.1 0.5 ± 0.3
Skin 0.6 ± 0.1 0.4 ± 0.1 0.06 ± 0.02 0.10 ± 0.05
Tail 1.3 ± 0.3 0.6 ± 0.1 0.23 ± 0.08 0.21 ± 0.04
Eye 0.27 ± 0.07 0.16 ± 0.04 0.03 ± 0.06 0.02 ± 0.04
Heart 0.5 ± 0.1 0.21 ± 0.06 0.03 ± 0.01 0.03 ± 0.03
Femur 0.3 ± 0.1 0.2 ± 0.1 0.01 ± 0.01 0.02 ± 0.03
Brain 0.081 ± 0.007 0.04 ± 0.02 0.007 ± 0.004 0.008 ± 0.001
Small intestineb 12.2 ± 10.8 5.6 ± 3.9 0.4 ± 0.2 1.7 ± 0.3
53
Blood 1.1 ± 0.2 1.2 ± 0.3 0.56 ± 0.03 0.6 ± 0.2
Tumour 1.6 ± 0.7 2.0 ± 0.5 1.2 ± 0.2 1.0 ± 0.4
Muscle 0.5 ± 0.2 0.56 ± 0.05 0.29 ± 0.05 0.4 ± 0.3
Lung 6.9 ± 3.3 6.8 ± 3.3 4.2 ± 0.4 4.5 ± 0.5
Kidney 4.1 ± 0.9 4.8 ± 2.2 1.7 ± 0.2 2.1 ± 0.5
Spleen 5.3 ± 2.2 6.3 ± 1.5 3.4 ± 0.2 3.9 ± 1.1
Liver 3.1 ± 0.9 2.1 ± 0.4 0.81 ± 0.06 0.9 ± 0.2
Large intestineb 3.3 ± 3.3 6.1 ± 2.5 1.6 ± 1.3 1.8 ± 0.8
Urine 285.9 ± 102.0 28.9 ± 10.7 15.6 ± 4.6 16.9 ± 9.1
Thyroid 4.4 ± 1.5 6.9 ± 1.3 5.2 ± 2.0 12.9 ± 9.1
Stomachb 12.8 ± 5.5 13.9 ± 2.7 9.8 ± 2.9 10.8 ± 4.6
Skin 2.1 ± 0.7 2.7 ± 0.5 1.7 ± 0.3 2.3 ± 0.4
Tail 2.5 ± 0.8 2.2 ± 0.2 1.3 ± 0.2 1.6 ± 0.3
Eye 0.7 ± 0.2 0.7 ± 0.2 0.48 ± 0.06 0.5 ± 0.1
Heart 2.2 ± 0.7 2.7 ± 0.6 1.22 ± 0.05 1.3 ± 0.4
Femur 1.1 ± 0.3 1.4 ± 0.7 0.61 ± 0.03 0.8 ± 0.4
Brain 0.19 ± 0.06 0.21 ± 0.07 0.12 ± 0.03 0.08 ± 0.02
Small intestineb 8.3 ± 7.9 3.2 ± 0.9 1.0 ± 0.1 1.2 ± 0.3
a Values are mean % ID/g ± SD (n = 4).
b Gastric and intestinal values include their contents.
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Table D.7: Biodistribution of 14b and 54 in Balb/c nude mice bearing the melanotic
melanoma xenograft HHMSX.
Organ 0.5 ha 2 ha 6 hb 16 hb
14b
Blood 0.5 ± 0.1 0.14 ± 0.03 0.014 ± 0.002 0.005 ± 0.001
Tumour 0.8 ± 0.2 0.5 ± 0.1 0.15 ± 0.09 0.06 ± 0.02
Muscle 0.35 ± 0.07 0.05 ± 0.03 0.003 ± 0.004 0.002 ± 0.002
Lung 1.2 ± 0.2 0.18 ± 0.03 0.022 ± 0.007 0.006 ± 0.001
Kidney 2.4 ± 0.5 0.60 ± 0.08 0.05 ± 0.03 0.013 ± 0.005
Spleen 0.8 ± 0.2 0.09 ± 0.02 0.011 ± 0.004 0.004 ± 0.003
Liver 2.3 ± 0.4 0.42 ± 0.04 0.08 ± 0.02 0.03 ± 0.01
Large intestinec 2.1 ± 1.1 3.4 ± 2.2 0.3 ± 0.2 0.008 ± 0.001
Urine 183.1 ± 109.1 107.6 ± 15.0 20.5 ± 18.4 0.10 ± 0.03
Thyroid 1.5 ± 0.3 0.4 ± 0.1 0.04 ± 0.02 0.004 ± 0.001
Stomachc 1.7 ± 1.5 0.6 ± 0.1 0.05 ± 0.02 0.006 ± 0.002
Skin 0.7 ± 0.1 0.20 ± 0.04 0.028 ± 0.007 0.007 ± 0.004
Tail 1.7 ± 0.5 0.5 ± 0.2 0.14 ± 0.08 0.2 ± 0.2
Eye 0.24 ± 0.04 0.05 ± 0.02 0.008 ± 0.003 0.003 ± 0.005
Heart 0.5 ± 0.1 0.098 ± 0.005 0.009 ± 0.002 0.004 ± 0.002
Femur 0.4 ± 0.1 0.07 ± 0.02 0.004 ± 0.004 0.003 ± 0.004
Brain 0.21 ± 0.06 0.023 ± 0.005 0.002 ± 0.001 0.001 ± 0.001
Small intestinec 3.1 ± 2.6 0.6 ± 0.4 0.05 ± 0.02 0.007 ± 0.002
54
Blood 1.04 ± 0.09 0.6 ± 0.2 0.48 ± 0.08 0.29 ± 0.09
Tumour 0.9 ± 0.7 0.9 ± 0.4 0.4 ± 0.3 0.4 ± 0.2
Muscle 0.6 ± 0.2 0.18 ± 0.09 0.2 ± 0.1 0.1 ± 0.1
Lung 5.5 ± 2.9 2.8 ± 0.9 3.8 ± 2.3 2.0 ± 0.9
Kidney 3.8 ± 0.6 2.1 ± 1.0 1.23 ± 0.8 0.9 ± 0.3
Spleen 3.4 ± 0.9 3.8 ± 1.5 2.5 ± 0.9 1.9 ± 0.9
Liver 2.2 ± 0.2 0.8 ± 0.3 0.6 ± 0.2 0.30 ± 0.03
Large intestinec 2.4 ± 1.6 2.5 ± 0.6 0.5 ± 0.1 0.5 ± 0.1
Urine 137.0 ± 70.4 149.1 ± 27.6 28.1 ± 17.2 5.0 ± 1.5
Thyroid 4.9 ± 3.4 3.4 ± 2.0 2.3 ± 0.8 1.1 ± 0.2
Stomachc 4.3 ± 4.0 11.2 ± 5.4 5.0 ± 1.3 4.4 ± 1.3
Skin 2.2 ± 1.0 2.0 ± 0.5 1.3 ± 0.5 1.1 ± 0.6
Tail 3.0 ± 1.7 1.2 ± 0.3 0.9 ± 0.2 0.6 ± 0.2
Eye 0.7 ± 0.4 0.5 ± 0.3 0.43 ± 0.05 0.3 ± 0.3
Heart 1.2 ± 0.3 1.9 ± 0.9 0.8 ± 0.1 0.9 ± 0.5
Femur 0.6 ± 0.3 0.5 ± 0.2 0.4 ± 0.1 0.4 ± 0.1
Brain 0.2 ± 0.2 0.16 ± 0.05 0.10 ± 0.06 0.10 ± 0.03
Small intestinec 2.5 ± 2.2 1.1 ± 0.2 0.71 ± 0.08 0.6 ± 0.2
a Values are mean % ID/g ± SD (n = 4).
b Values are mean % ID/g ± SD (n = 3).
c Gastric and intestinal values include their contents.
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Table D.8: Biodistribution of 14b and 54 in Balb/c nude mice bearing the amelanotic
melanoma xenograft SESX.
Organ 1 ha 4 h 16 h
14b
Blood 0.5 ± 0.1 0.05 ± 0.02 0.011 ± 0.001
Skin 1.1 ± 0.4 0.09 ± 0.02 0.022 ± 0.005
Heart 0.7 ± 0.7 0.03 ± 0.01 0.008 ± 0.003
Lung 0.6 ± 0.2 0.056 ± 0.005 0.018 ± 0.006
Liver 2.3 ± 0.5 0.26 ± 0.04 0.103 ± 0.004
Kidney 1.2 ± 0.9 0.15 ± 0.03 0.052 ± 0.004
Spleen 0.4 ± 0.1 0.032 ± 0.006 0.010 ± 0.003
Stomachb 6.4 ± 7.3 0.3 ± 0.1 0.02 ± 0.01
Small intestineb 7.5 ± 4.1 0.34 ± 0.02 0.03 ± 0.01
Eye 0.2 ± 0.1 0.001 ± 0.002 0.002 ± 0.004
Tumour 1.0 ± 0.3 0.47 ± 0.07 0.095 ± 0.006
Muscle 0.2 ± 0.1 0.02 ± 0.01 0.000 ± 0.000
Femur 0.2 ± 0.1 0.04 ± 0.04 0.001 ± 0.002
Urine – – 0.11 ± 0.09
Large intestineb 4.7 ± 4.5 1.2 ± 0.6 0.02 ± 0.02
54
Blood 0.5 ± 0.1 0.24 ± 0.08 0.10 ± 0.04
Skin 1.7 ± 0.4 0.7 ± 0.2 0.3 ± 0.1
Heart 1.2 ± 0.2 0.6 ± 0.1 0.23 ± 0.04
Lung 2.5 ± 1.9 1.1 ± 0.4 0.8 ± 0.1
Liver 1.6 ± 0.3 0.62 ± 0.02 0.210 ± 0.009
Kidney 2.0 ± 0.9 1.1 ± 0.3 0.42 ± 0.05
Spleen 3.7 ± 1.0 2.0 ± 0.7 0.8 ± 0.2
Stomachb 4.7 ± 3.1 3.2 ± 0.8 1.2 ± 0.4
Small intestineb 4.1 ± 2.1 0.48 ± 0.05 0.17 ± 0.05
Eye 0.3 ± 0.1 0.11 ± 0.02 0.05 ± 0.04
Tumour 1.3 ± 0.4 0.66 ± 0.07 0.15 ± 0.06
Muscle 0.4 ± 0.1 0.20 ± 0.09 0.04 ± 0.02
Femur 0.5 ± 0.2 0.29 ± 0.08 0.13 ± 0.03
Urine – – 1.3 ± 0.6
Large intestineb 3.5 ± 1.8 0.64 ± 0.08 0.2 ± 0.1
a Values are mean % ID/g ± SD (n = 3).
b Gastric and intestinal values include their contents.
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